 
  
 I6T-MC -AMBU(c) Clinical Protocol 
 
 
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients with Moderately to 
Severely Active Ulcerative Colitis (SHINE -1) 
 
NCT 04004611 
 
Approval Date: 23 -Oct-2021 
 
 
I6T-MC-AMBU (c) Clinical Protocol  Page 1 
LY3074828     Protocol I6T -MC-AMBU (c) 
A Multicenter, Open -Label PK Study of Mirikizumab  in 
Pediatric Patients with Moderate ly to Severely Active 
Ulcerative Colitis  
SHINE -1 
EUDRA CTA :  2019 -001298 -96 
 
Confidential Information  
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical  investigation of  
mirikizumab  (LY3074828) , unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries .   
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subjec t to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.  
Mirikizumab  (LY3074828)  
Eli Lilly and Company  
Indianapolis, Indiana USA 46285  
Document ID: VV-CLIN -008288  
Amendment ( c) Electronically Signed and Approved by Lilly  on date provided below . 
 
 
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 2 
LY3074828  Protocol Amendment Summary of Changes Table  
 
DOCUMENT HISTORY  
Document  Date  
Amendment b  30-Apr-2021  
Amendment a  26-Aug-2019  
Original Protocol  24-Apr-2019  
Amendment c  
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
The primary purpose of this amendment is to modify  dosing instructions for the ≥20-40 kg 
participants  during the maintenance period . Each participant will receive one injection of a  1 mL 
prefilled syringe inst ead of two 0.5  mL injections for SC maintenance dosing.  
Section # and 
Name  Description of Change  Brief Rationale  
Section 2 . 
Schedule of 
Activities  Updated notes for endoscopy 
with biopsies  procedure   Clarified  that a medical consult  is 
necessar y to omit endoscopy at the ETV 
visit 
Section 1 
Synopsis and 
Section 4. 
Objectives and 
Endpoints  
Section 5.1 
Overall 
Design  Figure  AMB U.1 Study design   
 Updated the study design figure to reflect 
the updated language in section 7.1 (see 
below)  
Section 7.1  
Treatments 
Administered, 
Table 
AMBU.3. 
Treatment 
Regimens: 
Week 12 
Clini cal 
Responders  Updated enrollment initiation  
criteria for the ≤40 kg cohort  
receiving 10 mg/kg dosing  To correct a prior protocol error and 
clarify enrollment of the 10 mg/kg  cohort 
opens after all patients in the 5  mg/kg 
cohort have enrolled AND at least 5 
patients  have had 2 doses  and the Week 4 
evaluation of PK samples and safety 
assessment have been completed  
Section 7.1 
Treatments 
Administered , Removed reference to maximum 
volume for injections  
 
 Study site feedback indicated that 
injecting 1  mL subcutaneously in patients  
weighing 20  kg to ≤40 kg is acceptable 
and importantly, avoid s 2 injections in a 
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 3 
LY3074828  Section # and 
Name  Description of Change  Brief Rationale  
Study Drug 
Administration   
 
 
 child . Therefore,  the maximum volume 
limitation  was removed  
 
Section 7.1.1. 
Packaging and 
Labeling  Updated information about study 
drug supplies  
 
 
Removed pharmacy manual 
reference  Updated content to state study drug will 
be provided as   
. 
 
The document name was revised 
internally; the “Pharmacy Manual” does 
not include study drug administration 
instructions   
Section 9.1.5. 
Determination 
of Responder 
Status/Loss of 
Response  and 
SoA 
comments  
  
 
   
 
Section 9.4.3.1 
Pregnancy 
Testing  More clearly define ‘women of 
childbearing potential’ and when 
urine pregnancy testing should 
be conducted  Feedback from clinical trial sites 
suggested prior wording was unclear. 
Providing a list of the po ssible categories 
relevant to our study population provides 
more clarity  
Section 10.2. 
Populations 
for Analyses , 
Table 
AMBU.6.  
Population 
Definitions  Updated description of the mITT 
population  To clarify that  the mITT is applicable for 
both induction and  maintenance periods  
Appendix 6. 
Permitted 
Medications 
with Dose 
Stabilization   
   
 
 
 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 4 
LY3074828  Table of Contents  
Section  Page  
Protocol I6T -MC-AMBU(c) A Multicenter, Open -Label PK Study of 
Mirikizumab in P ediatric Patients with Moderately to Severely 
Active Ulcerative Colitis SHINE -1 ................................ ................................ ......................... 1 
Protocol Amendment Summary of Changes Table  ................................ ................................ .......2 
Table of Contents  ................................ ................................ ................................ ............................. 4 
1. Synopsis  ................................ ................................ ................................ ................................ .11 
2. Schedule of Activities  ................................ ................................ ................................ ............ 16 
3. Introduction  ................................ ................................ ................................ ........................... 33 
3.1. Study Rationa le ................................ ................................ ................................ ................ 33 
3.2. Background ................................ ................................ ................................ ....................... 33 
3.2.1.  Disease State and Treatment Goals  ................................ ................................ .......... 33 
3.2.2.  Currently Available Treatments and Unmet Need  ................................ ................... 34 
3.2.3.  Interleukin -23 as a Therapeutic Target in Ulcerative Colitis  ................................ ...35 
3.2.4.  Preclinical and Clinical Studies of Mirikizumab  ................................ ..................... 35 
3.3. Benefit/Risk Assessment  ................................ ................................ ................................ ..36 
4. Objectives and Endpoints  ................................ ................................ ................................ ......38 
5. Study Design  ................................ ................................ ................................ ......................... 43 
5.1. Overall Design  ................................ ................................ ................................ .................. 43 
5.1.1.  Definit ion of Baseline  ................................ ................................ .............................. 45 
5.1.2.  Definition of Enrollment  ................................ ................................ .......................... 45 
5.2. Number of Participants  ................................ ................................ ................................ .....45 
5.3. End of Study Definition ................................ ................................ ................................ ....45 
5.4. Scientific Rationale for Study Design  ................................ ................................ .............. 45 
5.5. Justification for Dose  ................................ ................................ ................................ ........ 46 
6. Study Population  ................................ ................................ ................................ ................... 49 
6.1. Inclusion Criteria  ................................ ................................ ................................ .............. 49 
6.2. Exclusion Criteria  ................................ ................................ ................................ ............. 53 
6.2.1.  Rationale for Exclusion of Certain Study Candidates  ................................ ............. 59 
6.3. Lifestyle Restrictions  ................................ ................................ ................................ ........ 59 
6.4. Screen Failures  ................................ ................................ ................................ ................. 59 
6.4.1.  Allow ed Retesting of Screening Investigations  ................................ ....................... 60 
7. Treatments  ................................ ................................ ................................ ............................. 62 
7.1. Treatments Administered  ................................ ................................ ................................ .62 
7.1.1. Packaging and Labelling  ................................ ................................ .......................... 63 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 5 
LY3074828  7.2. Method of Treatment Assignment  ................................ ................................ .................... 64 
7.2.1.  Selection and Timing of Doses  ................................ ................................ ................ 64 
7.3. Blinding  ................................ ................................ ................................ ............................ 64 
7.4. Dosage Modification  ................................ ................................ ................................ ........ 64 
7.5. Preparation/Handling/Storage/Accountability  ................................ ................................ .64 
7.6. Treatment Compliance  ................................ ................................ ................................ .....65 
7.7. Concomitant Therapy  ................................ ................................ ................................ .......65 
7.7.1.  Corticosteroid Taper  ................................ ................................ ................................ 66 
7.7.2.  Vaccine Administration During the Study  ................................ ............................... 67 
7.8. Treatment after the End of the Study  ................................ ................................ ............... 67 
7.8.1.  Study Extensions  ................................ ................................ ................................ ......67 
7.8.2.  Treatment after Study Completion  ................................ ................................ ........... 67 
7.8.3.  Special Treatment Considerations  ................................ ................................ ........... 68 
7.8.3.1.  Premedication for Infusions  ................................ ................................ ............... 68 
7.8.3.2.  Management of Hypersensitivity, Infusion -Related 
Events, Infusion Site Reactions and Injection Site 
Reactions  ................................ ................................ ................................ ............ 68 
8. Discontinuation Criteria  ................................ ................................ ................................ ........ 70 
8.1. Discontinuation from Study Drug  ................................ ................................ .................... 70 
8.1.1.  Permanent Discontinuation from Study Drug  ................................ .......................... 70 
8.1.2.  Temporary Interruption (Withholding) of Study Drug  ................................ ............ 72 
8.1.3.  Discontinuation of Inadvertently Enrolled Patients  ................................ ................. 72 
8.2. Discontinuation from the Study  ................................ ................................ ........................ 73 
8.3. Lost to Follow -Up ................................ ................................ ................................ ............ 73 
9. Study Assessments and Procedures  ................................ ................................ ....................... 74 
9.1. Efficacy Assessments  ................................ ................................ ................................ .......74 
9.1.1.  Mayo Score  ................................ ................................ ................................ .............. 75 
9.1.2.  Endoscopy  ................................ ................................ ................................ ................ 77 
9.1.3.  Endoscopic Biopsies  ................................ ................................ ................................ 79 
9.1.4.  Pediatric Ulcerative Colitis Activity Index  ................................ .............................. 79 
9.1.5.  Determination of Responder Status/Loss of Response  ................................ ............ 79 
9.1.6.  Growth and Pubertal Assessments  ................................ ................................ ........... 80 
9.1.6.1.  Occipital Head Circumference  ................................ ................................ ........... 80 
9.1.6.2.  Height Velocity  ................................ ................................ ................................ ..81 
9.1.6.3.  Assessment of Puberty  ................................ ................................ ....................... 81 
9.1.7.  Health Outcomes Instruments  ................................ ................................ .................. 81 
9.1.8.  Histopathology Scoring Instrument  ................................ ................................ ......... 81 
9.1.9.  Exploratory Assessments  ................................ ................................ ......................... 82 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 6 
LY3074828  9.1.9.1.  Inflammatory Biomarkers  ................................ ................................ .................. 82 
9.1.9.2.  Patient -Reported Outcome/Observer -Reported Outcome 
Instruments for Exploratory Assessments  ................................ .......................... 82 
9.1.9.3.  Extraintestinal Manifestations  ................................ ................................ ............ 83 
9.1.9.4.  Physician -Reported Instrument  ................................ ................................ .......... 83 
9.1.10.  Appropriateness of Assessments  ................................ ................................ .............. 83 
9.2. Adverse Events  ................................ ................................ ................................ ................. 83 
9.2.1.  Serious Adverse Events  ................................ ................................ ........................... 84 
9.2.1.1.  Suspected Unexpected Serious Adverse Reactions  ................................ ........... 85 
9.2.1.2.  Regulatory Reporting Requirements for Serious Adverse 
Events  ................................ ................................ ................................ ................. 85 
9.2.2.  Adverse Events of Special Interest  ................................ ................................ .......... 86 
9.2.2.1.  Opportunistic Infections  ................................ ................................ ..................... 86 
9.2.2.2.  Systemic Allergic Reactions and Hypersensitivity Events  ................................ 86 
9.2.2.3.  Injection/Infusion Site Reactions  ................................ ................................ .......87 
9.2.2.4.  Cerebro -Cardiovascular and Venous Thromboemboli c 
Event Adjudication  ................................ ................................ ............................. 87 
9.2.3.  Complaint Handling  ................................ ................................ ................................ .87 
9.3. Treatment of Overdose  ................................ ................................ ................................ .....87 
9.4. Safety  ................................ ................................ ................................ ................................ 88 
9.4.1.  Vital Signs  ................................ ................................ ................................ ................ 88 
9.4.2.  Electrocardiograms  ................................ ................................ ................................ ..88 
9.4.3.  Laboratory Tests  ................................ ................................ ................................ ......88 
9.4.3.1.  Pregnancy Testing  ................................ ................................ .............................. 89 
9.4.3.2.  Hormone Testing  ................................ ................................ ................................ 89 
9.4.4.  Immunogenicity Assessments  ................................ ................................ .................. 89 
9.4.5.  Other Tests  ................................ ................................ ................................ ............... 90 
9.4.5.1.  Physical Examination  ................................ ................................ ......................... 90 
9.4.5.2.  Tuberculosis Testing  ................................ ................................ .......................... 91 
9.4.5.3. Chest Radiography  ................................ ................................ ............................. 93 
9.4.5.4.  Hepatitis B Testing  ................................ ................................ ............................. 94 
9.4.5.5.  Hepatitis C Testing  ................................ ................................ ............................. 95 
9.4.5.6. Depression and Suicidality  ................................ ................................ ................. 96 
9.4.5.7.  Stool Testing  ................................ ................................ ................................ ......97 
9.4.6.  Safety Monitoring  ................................ ................................ ................................ ....98 
9.4.6.1.  Hepatic Safety Monitoring  ................................ ................................ ................. 98 
9.5. Pharmacokinetics  ................................ ................................ ................................ .............. 99 
9.6. Pharmacodynamics  ................................ ................................ ................................ ......... 100 
9.7. Pharm acogenomics  ................................ ................................ ................................ ......... 100 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 7 
LY3074828  9.7.1.  Whole Blood Sample for Pharmacogenetic Research  ................................ ........... 100 
9.8. Biomarkers  ................................ ................................ ................................ ..................... 100 
9.9. Medical Res ource Utilization and Health Economics  ................................ .................... 101 
10. Statistical Considerations  ................................ ................................ ................................ ....102 
10.1.  Sample Size Determination  ................................ ................................ ............................ 102 
10.2.  Populations for Analyses  ................................ ................................ ................................ 102 
10.3.  Statistical Analyses  ................................ ................................ ................................ ......... 102 
10.3.1.  General Statistical Considerations  ................................ ................................ ......... 102 
10.3.1.1.  Missing Data Imputation  ................................ ................................ .................. 103 
10.3.2.  Treatment Group Comparability  ................................ ................................ ............ 103 
10.3.2.1.  Patient Disposition  ................................ ................................ ........................... 103 
10.3.2.2.  Patient Characteristics  ................................ ................................ ...................... 103 
10.3.2.3.  Concomitant Therapy  ................................ ................................ ....................... 103 
10.3.2.4.  Treatment Compliance  ................................ ................................ ..................... 103 
10.3.3.  Efficacy Analyses  ................................ ................................ ................................ ..104 
10.3.3.1.  Primary Analyses  ................................ ................................ ............................. 104 
10.3.3.2.  Secondary Analyses  ................................ ................................ ......................... 104 
10.3.3.3.  Tertiary/Exploratory Analyses  ................................ ................................ ......... 104 
10.3.4.  Safety Analyses  ................................ ................................ ................................ ......104 
10.3.5.  Pharmacokinetic/Pharmacodynamic Analyses  ................................ ...................... 105 
10.3.6.  Evaluation of Immunogenicity  ................................ ................................ ............... 105 
10.3.7.  Other Analyses  ................................ ................................ ................................ .......106 
10.3.7.1.  Subgroup Analyses  ................................ ................................ ........................... 106 
10.3.8. Data Snapshot and Interim Analyses  ................................ ................................ .....106 
10.3.8.1.  Data Snapshots  ................................ ................................ ................................ .106 
10.3.8.2.  Interim Analyses  ................................ ................................ .............................. 106 
11. References  ................................ ................................ ................................ ........................... 107 
12. Appendices  ................................ ................................ ................................ .......................... 111 
 
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 8 
LY3074828  List of Tables  
Table  Page  
Table  AMBU.1.  Schedule of Activities  ................................ ................................ ....................... 17 
Table  AMBU.2.  Objectives and Endpoints  ................................ ................................ .................. 38 
Table  AMBU.3.  Treatment Regimens:  Week 12 Clinical Responders  ................................ .......62 
Table  AMBU.4.  Treatment Regimens:  Week 12 Clinical Nonrespo nders  ................................ .63 
Table  AMBU.5.  Secondary Efficacy Endpoint Definitions in Study AMBU  ............................. 75 
Table  AMBU.6.  Population Definitions  ................................ ................................ ..................... 102 
 
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 9 
LY3074828  List of Figures  
Figure  Page  
Figure  AMBU.1.  Illustration of study design for clinical protocol I6T -MC-AMBU.  ................... 44 
Figure AMBU.2 . Comparison of interquartile range for average induction concentration 
for the doses planned in pediatric patients ≤40 kg relative to adults.  ............... 47 
Figure  AMBU.3.  Comparison of interquartile range for average maintenance 
concentration for the doses planned i n pediatric patients relative to 
adults.  ................................ ................................ ................................ ................ 48 
 
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 10 
LY3074828  List of Appendices  
Appendix  Page  
Appendix 1.  Abbreviations and Definitions  ................................ ................................ ......... 112 
Appendix 2.  Clinical Laboratory Tests  ................................ ................................ ................ 118 
Appendix 3.  Study Governance Considerations  ................................ ................................ ..120 
  .................. 125 
Appendix 5.  Prohibited Medications  ................................ ................................ .................... 127 
Appendix 6.  Permitted Medications with Dose Stabilization  ................................ .............. 130 
Appendix 7.  Ulcerative Colitis Disease Activity Measures  ................................ ................. 132 
Appendix 8.  Risk Factors for Latent Tuberculosis Infection  ................................ ............... 135 
Appendix 9.  Examples of Infections that May Be  Considered Opportunistic in the 
Setting of Biologic Therapy  ................................ ................................ ............ 137 
Appendix 10.  Provisions for Changes in Study Conduct During Exceptio nal 
Circumstances  ................................ ................................ ................................ .139 
Appendix 11.  Protocol Amendment I6T -MC-AMBU(b) Summary  
A Multicenter, Open -Label PK Study of Mirikizumab in Pediatric 
Patients with Moderately to Severely Active Ulcerative Colitis  ..................... 148 
 
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 11 
LY3074828  1. Synopsis  
Title of Study:  
A Multicenter, Open -Label  PK Study of Mirikizumab  in Pediatric Patients with Moderate ly to 
Severely Active Ulcerative Colitis . 
Rationale:  
Current treatments for pediatric patients with ulcerative colitis ( UC) have limitations with respect 
to efficacy, safety, and tolerability; in fact clinical trial data in pediatric populations is scant or 
lacking completely.  In addition, many treatments require close monitoring for adverse effects, 
which increases undue bur den to the child and family.  Thus, there is a substantial unmet need 
for the development, evaluation , and approval of efficacious, safe, and well -tolerated therapies 
for children and adolescents with UC.  Interleukin -23 (IL-23) has been implicated as a 
pro-inflammatory factor in mucosal inflammation in UC.   Study I6T -MC-AMBU (AMBU ) is an 
open-label study to evaluate the safety, pharmacokinetics  (PK), pharmacodynamics ( PD), and 
clinical response to mirikizumab to establish induction and maintenance doses to  evaluate in 
Phase 3, in children and adolescents  with UC , aged  2 to less than 18 years .  Study AMBU  will 
include  safety data following mirikizumab  treatment for at least 1 year.  
Objective(s)/Endpoints:  
Objectives  Endpoints  
Primary    
 To evaluate the pharmacokinetics (PK)  of 
mirikizumab treatment in pediatric patients   Clearance and volume of distribution of mirikizumab  
Secondary   
 To evaluate the  effect  of treatment with 
mirikizumab on achieving clinical remission  at 
Week 12 and/or Week 52   The pr oportion of patients in modified Mayo score  
(MMS ) clinical remission at Week 12  
 The proportion of patients in MMS clinical remission 
at Week 52  
 The proportion of patients in MMS clinical remission 
at Week 52 among the  MMS clinical remi tters at 
Week  12 (durable clinical remission)  
 The pro portion of patients in MMS clinical remission 
at Week 52 among the MMS clinical responders from 
Week 12  
MMS clinical remission  is defined as:   
 Stool frequency (SF) subscore = 0, or SF = 1, and  
 Rectal bleeding (RB) subs core = 0, and  
 Endoscop ic subscore (ES) = 0 or 1 (excluding 
friability)  
MMS clinical response  is defined below  
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 12 
LY3074828  Objectives  Endpoints  
 To evaluate the effect of treatment with 
mirikizumab on achieving clinical response  at 
Week 12 and/or Week 52   The proportion of pati ents in clinical response at 
Week 12  
 The proportion of patients in clinical response at 
Week 52  
 The proportion of patients in clinical response at 
Week 12 who  achieve clinical response at W eek 52  
Clinical response  is based on the MMS and is defined as:  
o A decrease in the MMS of ≥2 points and 
≥30% decrease from baseline, and  
o A decrease of ≥1 point in the RB subscore 
from baseline or a RB score of 0 or 1  
 To evaluat e the effect of treatment with 
mirikizumab  on achieving corticosteroid -free 
remission  without surgery among patients in 
clinical remission at Week 52 and receiving 
corticosteroids at baseline    The proportion of patients who are in MMS clinical 
remission at Week 52 without the use of 
corticosteroids  
 To evaluate the effect of treatment with  
mirikizumab  on PUCAI clinical remission  at 
Week 12 and/or Week 52   The proportion of patients i n PUCAI clinical 
remission at Week 12  
 The proportion of patients in PUCAI clinical 
remission at Week 52  
 The proportion of patients in PUCAI clinical 
remission at Week 12 who achieve clinical remission 
at Week 52  
 The proportion of patients in PUCAI clinical 
response at Week 12 who achieve clinical remission 
at Week 52  
PUCAI clinical remission  is defined as a PUCAI score 
of <10 points  
PUCAI clinical response  is defined below  
 To evaluate the effect of treatment with  
mirikizumab  on PUCAI clinical response  at 
Week 12 and/or Week 52   The proportion of  patients in PUCAI clinical 
response at Week 12  
 The proportion of patients in PUCAI clinical 
response at Week 52  
 The proportion of patients in PUCAI clinical 
response at Week 12 who  achieve PUCAI clinical 
response at W eek 52  
PUCAI clinical response  is defined as a reduct ion in 
baseline PUCAI score of ≥ 20 points  
 
  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 13 
LY3074828  Objectives  Endpoints  
 To evaluate the effect  of treatment with  
mirikizumab on achieving endoscopic remission 
at Week 12  and/or Week 52   The proportion of patien ts in endoscopic remission at 
Week 12  
 The proportion of patients in endoscopic remission at 
Week 52  
 The proportion of patients in endoscopic remission at 
Week 12 who maintain endoscopic rem ission at 
Week 52  (durable endoscopic remission)  
Endoscopic remission  is defined as:  
o ES = 0 or 1 (excluding friability)  
 To evaluate the effect of treatment with  
mirikizumab on achieving ES = 0 at Week 12 or 
Week 52    The proportion of patients wi th ES = 0 at Week 12  
 The proportion of patients with ES = 0 at We ek 52  
 To evaluate the effect of treatment with  
mirikizumab  on symptomatic remission  over 
time  Proportion of patient s in symptomatic remission at 
applicable study visits  
Symptomatic remission  is defined as:  
o SF = 0, or SF =  1 with a ≥ 1-point decrease 
from baseline and  
o RB = 0  
 To evaluate the effect of  treatment with  
mirikizumab  on height velocity at Weeks 12, 24, 
and 52   Observed height velocity  by gender and age group 
will be calculated at baseline, Week 12, Week 2 4, 
and Week 52  
 To evaluate the effect of treatment with 
mirikizumab  on weight throughout the trial   Change from baseline in weight (kg) at all study 
visits by gender and age group  
 To evaluate the effect of treatment with 
mirikizumab  on pubert al development  throughout 
the trial  in appropriate patient groups   Hormone levels and/or other related clinical 
measures will be evaluated  
  
 
 
 To evaluate histologic -endoscopic mucosal 
remission  following mirikizumab  treatment at 
Week  12 or Week 52   Proportion of patients with histologic -endoscopic 
mucosal remission  at Week  12 
 Proportion of patients with histologic -endoscopic 
mucosal remission  at Week  52 
Histologic -endoscopic mucosal remission  is defined as 
achieving both  histologic  remission  and endoscopic  
remission .  Histologic remission  will be  defined in the 
SAP. 
  
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 14 
LY3074828  Objectives  Endpoints  
 To evaluate the development of anti-mirikizumab  
antibodies  and their effect on efficacy, safety, and 
mirikizumab exposure   Proportion of patients who have treatment -emergent 
anti-drug antibodies (TEADA)  
 Relationship between TEADA and efficacy  
 Relationship between TEADA and safety  
 Relationship between TEADA and mirikizumab PK  
  
   
 
 
Abbreviations:  NRS = numeric rating scale; PUCAI = Pediatric  Ulcerative Colitis Activity Index ; SAP = statistical 
analysis plan . 
 
Summary of Study Design:    
Study AMBU  is a multicenter, Phase 2 , open -label study  designed to evaluate the safety, PK, 
PD, and clinical response of mirikizumab in pediatric patients, and to provide data for dose 
confirmation for Phase 3.  The study population  includes  pediatric patients with moderately to 
severely active UC , who have an inadequate response to, loss of response to, or are intolerant to 
non-biologic therapy for UC ( biologic -naive ), and/or those who have been exposed to at least 1 
biologic and/or Janus kinase ( JAK) inhibitor therapy for UC (biologic/ JAK inhibitor -
experienced).  
Treatment Arms and Duration:    
Patients weighing >40  kg will receive a mirikizumab induction dose of 300 mg via intravenous 
(IV) infusion  and patients weighing ≤ 40 kg will receive 5 or 10 mg/k g via IV infusion  at 
Weeks  0, 4, and 8 .  Patients who have met the clinical response criteria at Week 12 will receive 
subcutaneous (SC)  maintenance doses of 200 mg (weight > 40 kg), or 100 mg (weight  >20 kg to 
≤40 kg), or 50 mg (weight ≤ 20 kg) every 4 weeks (Q4W) from Weeks 12 to 48.  Patients who 
have not achieved clinical response  at Week 12 may receive extended induction at the  next 
higher dose, or will be discontinued.   In cases where there is no higher dose, patients may receive 
extended in duction dosing  at the current dose.  
Number of Patients :  
Approximately 60 patients with moderately to severely active UC will be screened to enroll  
approximately  30 patients .   
Statistical Analysis:  
Analyses of the PK of mirikizumab and relationships between exposure and the efficacy  
endpoints will be conducted.  For both the PK and exposure –response analyses, intrinsic and 
extrinsic factors will be evaluated to determine their impact.  Comparisons of adult and pediatric 
PK and exposure –response will b e performed and may be combined if appropriate.   
The PK of  mirikizumab  (primary objective ) will be characterized at interim analysis points using 
graphical evaluations and mixed -effect (population PK) model ling approaches  using the 
available induction and maintenance mirikizumab concentration data .  The model ling will be 
used to understand the impact of factors , such as body weight and age, to estimate the exposures 
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 15 
LY3074828  expected prior to enrolling the 10 mg/kg dose  group in th is study  using  interim analyses of PK 
data, and to confirm the planned doses  for the Phase 3 study .  
  
Efficacy analyses for the induction period  and the maintenance  period  will be conducted on the  
modified intent -to-treat (ITT) population.  Safety analyses for the induction period  and the 
maintenance period  will be conducted on the induction safety population and the maintenance 
safety population,  respectively.   
Descriptive summaries by treatment, by visit, and by weight group for efficacy endpoints 
(secondary objectives) will be performed using nonresponde r imputation (NRI) methodology.  
Safety data will be summarized by dose.  Safety assessments will include adverse events , 
laboratory analytes, vital signs , and questionnaires to assess the existence and severity of 
depression . 
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 16 
LY3074828  2. Schedule of Activities  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 17 
LY3074828  Table  AMB U.1. Schedule of Activities   
 Screening  Treatment Period  Notes:  
Visit No.  V1  V2  V3 V4 V5 V6  V7 V8 V9  V10 
Study Week   
Study Days  
 
Patient assent (if appropriate) 
and parent/legal guardian 
informed consent   
X           
Inclusion/exclusion criteria  X X          
 
Demographic information, 
medical and surgical history   
X          
Pre-existing (current) medical 
conditions  X           
Review vaccine status  X           
Concomitant medication 
review (including 
corticosteroid use)   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Review AEs  X X X X X X X X X X  
Tobacco /nicotine  use X X    X   X  
Alcohol /caffeine  use X          
Investigational Product  Administration  
Assignment to treatment 
weight cohort   X          
           
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 18 
LY3074828   Screening  Treatment Period  Notes:  
Visit No.  V1  V2  V3 V4 V5 V6  V7 V8 V9  V10 
Study Week   
Study Days  
        
Physical E valuation  
 
Vital signs (temperature, BP 
using an appropriately sized 
cuff, and pulse rate )  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X 
Occipital head circumference   X    X   X  
Weight  X X X X X X X X X X 
 
Height   
X  
X     
X    
X  
Physical examination  X X X X X X   X  
Evaluate for EIMs  X X X X X X X X X X 
 
12-lead ECG (locally read)  
  
X      
X     
Laboratory Investigations  
Urinalysis  X           
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 19 
LY3074828   Screening  Treatment Period  Notes:  
Visit No.  V1  V2  V3 V4 V5 V6  V7 V8 V9  V10 
Study Week   
Study Days  
 
 
Serum pregnancy test   
 
Xa          
 
 
 
Urine pregnancy test    
 
 
X   
 
 
X  
 
 
X  
 
 
X  
 
 
X  
 
 
X  
 
 
X  
 
 
X 
 
 
 
Hormone collection   
       
     
 
HIV/HBV/HCV testing  Xa           
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 20 
LY3074828   Screening  Treatment Period  Notes:  
Visit No.  V1  V2  V3 V4 V5 V6  V7 V8 V9  V10 
Study Week   
Study Days  
 
 
 
 
HBV DNA   
 
 
 
Xa      
 
 
 
Xa    
 
 
 
X  
 
Chemistry /Hematology  
PK assessment            
    Pre-dose PK sample     X X Xa X  X  
    Post-dose PK sample   X   X      
    PK sample    X        
Immunogenicity (ADA) 
samples    
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 21 
LY3074828   Screening  Treatment Period  Notes:  
Visit No.  V1  V2  V3 V4 V5 V6  V7 V8 V9  V10 
Study Week   
Study Days  
 
 
 
 
 
Hypersensitivity testing (if 
applicable)    
 
 
 
 
Xa 
Pharmacogenomics blood 
sample  
 
TB testing   
Xa          
C-reactive protein   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 22 
LY3074828   Screening  Treatment Period  Notes:  
Visit No.  V1  V2  V3 V4 V5 V6  V7 V8 V9  V10 
Study Week   
Study Days  
Additional Safety Tests  
Chest radiography for TB 
screening  (optional – see 
comment)   
 
X          
TB Monitoring  
C-SSRS  
CDI 2 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 23 
LY3074828   Screening  Treatment Period  Notes:  
Visit No.  V1  V2  V3 V4 V5 V6  V7 V8 V9  V10 
Study Week   
Study Days  
Stool Samples  
 
 
Stool culture and Clostridium 
difficile  toxin   
 
X          
Fecal sample for fecal 
calprotectin and exploratory 
biomarker sample  
Endoscopic Procedure  
Endoscopy with biopsies  X     X     
Tissue samples for 
exploratory biomarkers  
Ulcerative Colitis Disease Activity Assessments  
Diary dispensed  X           
 
 diary compliance 
review    
X  
X  
X  
X  
X  
X  
X  
X  
X 
PGA  
PUCAI  
Health Outcome s Assessment                                                                 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 24 
LY3074828   Screening  Treatment Period  Notes:  
Visit No.  V1  V2  V3 V4 V5 V6  V7 V8 V9  V10 
Study Week   
Study Days  
PGI-C    X X X     
 
Visits 1 1 to Post -treatment Follow -up 
 Treatment  Period   Post-treatment 
Follow -up Notes  
Visit No.  V11 V12 V13 V14 V15 V16  N/A  V997b V801  V802c 
Study Week  
Study Days      
 
Concomitant medication 
review (including 
corticosteroid use)   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Revie w AEs  X X X X X X X X X X  
 
Tobacco /nicotine  use       
X  
X  
X   
Investigational Product  Administration  
 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 25 
LY3074828  Visits 1 1 to Post -treatment Follow -up 
 Treatment  Period   Post-treatment 
Follow -up Notes  
Visit No.  V11 V12 V13 V14 V15 V16  V801  V802c 
Study Week  
Study Days      
 
  
        
Physical Evaluation  
 
Vital signs (temperature, BP 
using appropriate size cuffs, 
and pulse rate )  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X 
Occipital head circumference   X    X X    
Weight  X X X X X X X X X X 
Heigh t       X X    
Physical examination   X   X X X X X X 
Evaluate for EIMs  X X X X X X X X X X  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 26 
LY3074828  Visits 1 1 to Post -treatment Follow -up 
 Treatment  Period   Post-treatment 
Follow -up Notes  
Visit No.  V11 V12 V13 V14 V15 V16  V801  V802c 
Study Week  
Study Days      
 
 
12-lead ECG (locally read)        
 
X  
 
X    
Laboratory Investigations  
 
 
 
 
Urine pregnancy test   
 
 
 
X  
 
 
 
X  
 
 
 
X  
 
 
 
X  
 
 
 
X  
 
 
 
X  
 
 
 
X  
 
 
 
Xb  
 
 
 
X  
 
 
 
X 
 
 
 
Hormone collection    
     
  
    
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 27 
LY3074828  Visits 1 1 to Post -treatment Follow -up 
 Treatment  Period   Post-treatment 
Follow -up Notes  
Visit No.  V11 V12 V13 V14 V15 V16  V801  V802c 
Study Week  
Study Days      
 
 
 
 
 
HBV DNA    
 
 
 
 
X     
 
 
 
 
Xa  
 
 
 
 
Xa    
 
 
 
 
Xa 
 
 
Chemistry/ Hematology            
 
PK assessment  
   
X     
Xa  
Xa    
Xa 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 28 
LY3074828  Visits 1 1 to Post -treatment Follow -up 
 Treatment  Period   Post-treatment 
Follow -up Notes  
Visit No.  V11 V12 V13 V14 V15 V16  V801  V802c 
Study Week  
Study Days      
Immunogenicity (ADA) 
samples            
C-reactive protein   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 29 
LY3074828  Visits 1 1 to Post -treatment Follow -up 
 Treatment  Period   Post-treatment 
Follow -up Notes  
Visit No.  V11 V12 V13 V14 V15 V16  N/A  V802c 
Study Week  
Study Days      
 
 
 
 
 
 
 
 
Hypersensitivity testing (if 
applicable)   
 
 
 
 
 
 
 
Xa     
Pharmacogenomics blood 
sample  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 30 
LY3074828  Visits 1 1 to Post -treatment Follow -up 
 Treatment  Period   Post-treatment 
Follow -up Notes  
Visit No.  V11 V12 V13 V14 V15 V16  V801  V802c 
Study Week  
Study Days      
Additional Safety Tests  
TB Monitoring  
CDI 2  
Stool Samples  
Fecal sample for fecal 
calprotectin and exploratory 
biomarker sample  
Endoscopy Procedure  
 
Endoscopy with biopsies  
Tissu e samples for exploratory 
biomarkers  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 31 
LY3074828  Visits 1 1 to Post -treatment Follow -up 
 Treatment  Period   Post-treatment 
Follow -up Notes  
Visit No.  V11 V12 V13 V14 V15 V16  V801  V802c 
Study Week  
Study Days      
Ulcer ative Colitis Disease Activity Assessments  
 
 
 diary compliance review   
 
X  
 
   X  
 
X  
 
X  
 
X  
 
X  
 
X    
Diary device collected       X X    
PGA  
PUCAI  
Health Outcomes Assessmen t                                                                        
PGI-C 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 32 
LY3074828  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 33 
LY3074828  3. Introduction  
3.1. Study Rationale  
Ulcerative colitis (UC) in pediatric patients remains a disease with high morbidity marked by a 
relapsing and remitting clinical course.  The unmet medical need for pediatric UC treatment 
exists in 3 primar y areas:   
 To provide new treatments that can induce and maintain remission in patients who have 
not sufficiently responded to current ly available  treatment regimens .  
 To improve treatment outcomes such that the use of corticosteroids is reduced or 
eliminated, thus avoiding corticosteroid -induced adverse effects .  
 To provide new treatments with improved safety profiles.   
Mirikizumab (LY3074828) is a humanized immunoglobulin G4 monoclonal antibody  that binds 
to the p19 subunit of interleukin -23 (IL -23), a cytokine that has been implicated in  mucosal 
inflammation.   This study will provide  dose evaluation in pediatric patients aged 2 to 17  years , 
efficacy data in induction and maintenance periods, and safety data following mirikizumab  
treatment for approximately  1 year.  
3.2. Background  
3.2.1.  Disease State and Treatment Goals  
Ulcerative  colitis  is a chronic relapsing a nd remitting disease  characteri zed by inflammation, 
ulcerati on, and bleeding in the colon.   Inflammation in UC is confined to the mucosal surface of 
the rectum and colon.  Ulcerative  colitis  is thought to be caused by a dysregulated immune 
response to host intestinal microflora.   
The prevalence of pediatric  UC over time is increasing as eviden ced by a population -based, 
nationwide cohort stud y based in Canada (Benchimol et al. 2009 [Canada]).  The prevalence of 
UC in the United States ( US) pediatric population as reported in the literature ranges between 
25,459 (Betteridge et al. 2013; US Census Bureau [WWW]) and 27,923 people (Kappelman et 
al. 2013; US Census Bureau [WWW]).   In addition , although at least 1 study  reported higher 
male versu s female prevalence of UC (Button et al. 2010  [United Kingdom (UK)]), other studies 
reported the opposite or no significant differences between genders (Kappelman et al. 2013 [US]; 
Di Domenicantonio et al. 2014 [Italy]).  
The management of UC in children an d adolescents is multifactorial and is based on treatment 
goals of :  
 induction of remission  with endoscopic healing   
 maintenance of r emission , and  
 longer  term prevention of cancer of the affected bowel.   
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 34 
LY3074828  Other factors that influence management of pediatric patients with UC include :  
 disease severity  
 disease distribution (pancolitis, left -sided colitis, or  proctitis )  
 response to and tolerance of previous treatments , and  
 comorbidities.   
Age-related considerations ( for example,  growth, puberty, and bone mineral density accretion) 
and patient and caregiver preferences also influence treatment plans.  
Given this information and the unmet medical need to provide an effective therapy for pediatric 
patients, this Phase 2  study is being conducted to generat e pharmacokinetic ( PK) and clinical 
response data to support  clinical development  for use of mirikizumab  in pediatric patients with 
moderately  to severely active UC. 
3.2.2.  Currently Available Treatments  and Unmet Need   
Remission rates in pediatric UC have been e valuated in pediatric clinical trials and retrospective  
reviews, and these evaluations have indicated that 29%  to 50% of children with 
moderate -to-severe  disease achieve d steroid -free remission at 1 year (Hyams et al. 2006, 2011, 
2012; Zeisler et al.  2013) .  Current treatments for pediatric patients with UC have significant 
limitations with respect  to efficacy, safety, and tolerability.  In addition, many treatments require 
close monitoring for  adverse effects, which increases undue burden on the child and family.  
Thus, there is a  substantial unmet need for the development and approval of efficacious, safe, 
and well -tolerated  therapies for children and adolescents with UC.  
To date, the anti-tumor necrosis factor ( TNF ) antibody , infliximab , is the only biologic therapy 
approved to treat UC in pediatric patients.  Although anti -TNF therapy has improved disease 
course in UC, lack of efficacy and loss of response continue to be a concern in this patient 
population  (Hyams et al. 2012).  
The safet y profile of current therapies, including infliximab, may also limit their use in some 
patients.  Treatment with infliximab is associated with an increased risk for serious infections 
leading to hospitali zation or death, including tuberculosis  (TB) , bacter ial sepsis, invasive fungal 
infection ( for example , histoplasmosis), and infections caused by other opportunistic pathogens.  
Lymphoma and other malignancies, some fatal such as hepatosplenic T -cell lymphoma, have 
also been reported in children and adolesc ent patients treated with TNF blockers , particularly 
when  these agents are used in combination with immunomodulators .  In addition, the 
development of anti -TNF antibodies is associated with acute infusion reactions, delayed 
hypersensitivity reactions, decr eased serum drug levels, and loss of response (Miele et al. 2004 ), 
leading to potentially significant safety and efficacy concerns.    
While treatment with corticosteroids is effective in inducing clinical response or remission in the 
majority of patients, almost 50% of patients develop corticosteroid dependence and require 
additional medic ation to successfully discontinue corticosteroids (Jakobsen et al. 2011b).  
Corticosteroids are not effective in maintaining remission in patients with UC, and long -term 
corticosteroid therapy is limited by the potential for significant adverse effects.  Although 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 35 
LY3074828  immunomodulatory therapies , such as azathioprine (AZA), 6 -mercaptopurine (6 -MP), 
tacrolimus, and methotrexate (MTX) , are used in clinical practice to treat moderat e-to-severe UC 
in pediatric patients, there is limited  evidence of efficacy from adequate and well -controlled 
trials in pediatric patients to recommend the appropriate and safe use of these therapies . 
3.2.3.  Interleukin -23 as a Therapeutic Target in Ulcerative Colitis  
Interleukin -23 is a member of the IL -12 family of cytokines.  It is a heterodimeric protein 
composed of 2  subunits:  the IL -12p40 subunit, which is shared by IL -12, and the IL -23p19 
subunit, which is specific to IL -23.   
Interleukin -23 expression is enriched in the intestine of patients with active UC.  In addition, 
genome -wide association scans identified common variants (single nucleotide polymorphisms) 
in molecules in the IL -23 signaling pathway that modify the risk of UC and/or Crohn’s disease 
(CD) in humans, including IL -23 receptor , STAT3, and Janus kinase (JAK) 2 (Jostins et al. 
2012).  Taken together, these data provide evidence for IL -23/Th17 pathway  as a therapeutic 
target in UC.   
Available clinical data with mirikizumab (St udy I6T -MC-AMA C [AMAC] ) support such a 
hypothesis.  Published clinical data show efficacy in inflammatory bowel disease  (IBD) for 
ustekinumab, risankizumab, brazikumab , and mirikizumab , and support the role of IL -23 in IBD . 
3.2.4.  Preclinical and Clinical Studies of Mirikizumab  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 36 
LY3074828  Additional preclinical data are summarized in the Investigator’s Brochure ( IB). 
A number  of clinical trials of m irikizumab  have been completed or are currently ongoing in 
patients with psoriasis, UC , and CD.  Data from these studies are summarized in the IB.   
Ongoing studies in adult patients with UC include the Phase 2 study AMAC and the Phase 3 
LUCENT program comprising of Study I6T-MC-AMAN (AMAN ; mirikizumab/placebo 
induction ), Study I6T-MC-AMBG (AMBG ; mirikizumab/placebo maintenance ), and Study I6T-
MC-AMAP ( mirikizumab open -label extension ). 
Study AMAC is a Phase 2, placebo -controlled, dou ble-blind clinical trial of mirikizumab in 
patients with moderate -to-severe UC, for which induction and maintenance results are available.  
In the 12 -week induction period, mirikizumab demonstrated efficacy for both endoscopic as well 
as symptomatic indice s as assessed by multiple measures (Sandborn et al. 2018).  Overall 
adverse event (AE) frequencies were similar for mirikizumab -treated and placebo -treated 
patients (Sandborn et al. 2018).  In the maintenance period through Week 52, mirikizumab 
demonstrate d durable efficacy for both endoscopic , as well as symptomatic indices:  among 
patients in clinical remission at Week 12, 61.1% ( every 4 weeks [ Q4W ]) and 38.5% ( every 
12 weeks [ Q12W ]) remained in clinical remission at Week 52.  There were few serious adver se 
events ( SAEs ) and few discontinuations due to AEs over 52 weeks (D’Haens et al. 2019).  
There were no unexpected adverse findings that would preclude clinical development in pediatric 
patients aged 2 through 17  years .  
3.3. Benefit/Risk Assessment  
Ulcerative colitis  remains an important public health challenge  for which there are currently few 
therapies available and no cure .  Although the pathogenesis and disease course of UC show 
similarities in patients affected in childhood and adulthood, many pediatric pa tients with UC 
have demonstrated more extensive disease and more severe disease course compared with adult 
patients with UC (Jakobsen  et al. 2011a).  Given the inevitably long -term medical problems 
caused by UC along with the adverse effects and limitation s of the current therapies, more 
effective and safer treatment options are needed for pediatric patients .   
At the time of this benefit/risk assessment , mirikizumab  has demonstrated efficacy in blinded, 
placebo -controlled , Phase 2 studies in UC (Sandborn e t al. 2018; D’Haens et al. 2019) and 
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 37 
LY3074828  psoriasis (Reich et al. 2017).  E valuation of unblinded safety data from the completed and  
ongoing psoriasis, UC , and CD studies  with dose regimens of  up to 1000 mg intravenous ( IV) 
Q4W  for up to 52 weeks , up to 3 00 mg SC Q8W for up to 104 weeks, and up to 300 mg SC 
Q4W for up to 40 weeks, have shown a safety profile generally consistent with the IL -23 
antibody class .  These data are summarized in the IB.   Across the ongoing Phase 2 mirikizumab 
studies, i mmediate hyperse nsitivity reactions, including 2 reports of immediate, infusion -related 
hypersensitivity events consistent with anaphylaxis, have been reported at the onset or during the  
IV infusion of mirikizumab .  Such reactions are considered by the sponsor to be relat ed to 
mirikizumab and hence , have been identified as adverse drug reactions (ADRs).   The protocol 
includes specific measures for reducing the incidence and for management of study drug infusion 
rate and observation during and after infusion.  Consult the m ost current IB for information 
regarding ADRs and potential risks with mirikizumab.   
Given the data from the Phase 2 study in UC, data from other clinical studies completed to date , 
and the open -label design ensuring active treatment is available to all s tudy participants, potential 
benefit to patients who receive mirikizumab while participating in Study I6T-MC-AMBU 
(AMBU ) may be reasonably anticipated.  
As colonos copies are required  in this study , there are potential  risks associated with the 
procedure , such as a reaction to sedation/anest hesia or the potential of perforation .  Personnel 
knowledgeable and skilled in the administration of sedation/anesthesia to children will be used to 
minimize this risk.  
In summary, the efficacy and safety data from the Phase 2 UC study AMAC support the 
continued clinical development of mirikizumab in pediatric patients with UC.  
More information about the known and expected benefits, risks, SAEs , and reasonably 
anticipated AEs of mirikizumab  are found in the IB.  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 38 
LY3074828  4. Objective s and Endpoints  
Table  AMBU .2 shows the objectives and endpoints of the study.  
Table  AMBU .2. Objectives and Endpoints  
Objectives  Endpoints  
Primary    
 To evaluate the pharmacokinetics (PK)  of 
mirikizumab treatment in pediatric patients   Clearance and volume of distribution of mirikizumab  
Secondary   
 To evaluate the  effect  of treatment with 
mirikizumab  on achieving clinical remission  at 
Week 12 and/or Week 52  The proportion of patients in  modified Mayo score 
(MMS)  clinical remission at Week 12  
 The proportion of patients in MMS clinical remission 
at Week 52  
 The proportion of patients in MMS clinical remission 
at Week 52 among the MMS clinical remitters at 
Week  12 (durable clinical remission)  
 The proportion of patients in MMS clinical remission 
at Week 52 among the MMS clinical responders from 
Week 12  
MMS  clinical remission  is defined as:   
 Stool frequency (SF) subscore  = 0, or SF =  1, and 
 Rectal bleeding (RB) subscore = 0 , and 
 Endoscopic subscore (ES) = 0 or 1 (excluding 
friability)  
MMS clinical response  is defined below  
 To evaluate the effect  of treatment with 
mirikizumab  on achieving clinical response  at 
Week 12 and/or Week 52  The proporti on of patients in clinical response at 
Week 12  
 The proportion of patients in clinical response at 
Week 52  
 The proportion of patients in clinical response at 
Week 12 who  achieve clinical response at Week  52 
Clinical response  is based on the MMS and is defined  as: 
o A decrease in the MMS of ≥ 2 points and 
≥30% decrease from baseline, and  
o A decrease of ≥1 point in the RB subscore 
from baseline or a RB score of 0 or 1  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 39 
LY3074828  Objectives  Endpoints  
 To evaluat e the effect of treatment with 
mirikizumab on achieving corticosteroid -free 
remission  without surgery among patients in 
clinical remission at Week 52 and receiving 
corticosteroids at baseline    The proportion of patients who are in MMS clinical 
remission at Week 52 without the use of 
corticosteroids  
 To evaluate the effect of treatment with  
mirikizumab  on PUCAI clinical remission  at 
Week 12 and/or Week 52   The proportion of patients in PUCAI clinical 
remission at Week 12  
 The proportion of patients in PUCAI clinical 
remission at Week 52  
 The proportion of patients in PUCAI clinical 
remission at Week 12 who achieve clinical remission 
at Week 52  
 The proportion of patients in PUCAI clinical 
response at Week 12 who achieve clinical remission 
at Week 52  
PUCAI clinical remission  is defined as a PUCAI score 
of <10 points  
PUCAI clinical response  is defined below  
 To evaluate the effect of treatment with  
mirikizumab  on PUCAI clinical response  at 
Week 12 and/or Week 52   The proportion of p atients in PUCAI clinical 
response at Week 12  
 The proportion of patients in PUCAI clinical 
response at Week 52  
 The proportion of patients in PUCAI clinical 
response at Week 12 who  achieve PUCAI clinical 
response at W eek 52  
PUCAI clinical response  is defined as a reduc tion in 
baseline PUCAI score of ≥ 20 points  
 To evaluate the effect  of treatment with  
mirikizumab on achieving  endoscopic remission 
at Week 12  and/or Week 52   The proportion of patie nts in endoscopic remission at 
Week 12  
 The proportion of patients in endoscopic remission at 
Week 52  
 The proportion of patients in endoscopic remission at 
Week 12 who maintain endoscopic remission at 
Week 52  (durable endoscopic rem ission)  
Endoscopic remission  is defined as:  
o ES = 0 or 1 (excluding friability)  
 To evaluate the effect of treatment with 
mirikizumab on achieving ES = 0 at Week 12 or 
Week 52    The proportion of patients wi th ES = 0 at Week 12  
 The p roportion of patients with ES = 0 at W eek 52  
  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 40 
LY3074828  Objectives  Endpoints  
 To evaluate the effect of treatment with  
mirikizumab  on symptomatic remission  over 
time  Proportion of patients in symptomatic remission at 
applicable study visit s 
Symptomatic remission  is defined as:  
o SF = 0, or SF =1 with a ≥ 1 -point decrease 
from baseline and  
o RB = 0  
 To evaluate the effect of treatment with 
mirikizumab  on height velocity at Weeks 12, 24, 
and 52   Observed height velocity  by gender and age group 
will be calculated at baseline, Week 12, Week 2 4, and 
Week 52  
 To evaluate the effect of treatment with 
mirikizumab  on weight throughout the trial   Change from baseline in weight (kg) at all study visits 
by gender and age group  
 To evaluate the effect of treatment with 
mirikizum ab on pubert al development  throughout 
the trial  in appropriate patient groups   Hormone levels and/or other related clinical measures 
will be evaluated  
 
 To evaluate histologic -endoscopic mucosal 
remission  following mirikizumab  treatment at 
Week  12 or Week 52   Proportion of patients with histologic -endoscopic 
mucosal remission  at Week  12 
 Proportion of patients with histologic -endoscopic 
mucosal remission  at Week  52 
Histologic -endoscopic mucosal remission  is defined as 
achieving both  histologic  remission  and endoscopic  
remission .  Histologic remission  will be  defined in the 
SAP. 
 To evaluate the development of anti-mirikizumab  
antibodies  and their effect on  
  Proportion of patients who have treatment -emergent 
anti-drug antibodies (TEADA)  
 
 
 
   
Exploratory   
 To evaluate the effect of treatment with 
mirikizumab  on changes in biomarker s  Change from baseline in fecal calprotectin  
 Change from baseline in C-reactive protein  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 41 
LY3074828  Objectives  Endpoints  
  
 To evaluate the time to symptomatic 
response   Time to symptomatic response  (defined as  at 
least a  in the 
composite clinical endpoint of the sum of SF and 
RB subscores ) 
 To evaluate the time to symptomatic 
remission   Time to symptomatic remission  (defined as  
SF = 0, or SF =  1 with a ≥1 -point decrease from 
baseline,  and RB = 0)  
 To evaluate  the numerical value and change 
from baseline of individual MMS subscores  
and the composite symptom subscore over 
time in patients receiving mirikizumab   The numerical value and change from baseline in  each 
of the following items :   
o SF (Weeks 2, 4, 8, 12, 24, 3 6, and 52)  
o RB (Weeks 2, 4, 8, 12, 24, 36, and 52)  
o ES (Weeks 12 and 52)  
o The composite clinical endpoint of the sum of the 
SF and RB subscores  (Weeks  2, 4, 8, 12, 24, 36, 
and 52 ) 
 
 
 
 
 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 42 
LY3074828  Abbreviations:  NRS = numeric rating scale; PGI-C = Patient’s Global Impression of Change; PGRS = Patient’s 
Global Rating of Severity;  PUCAI = Pediatric  Ulcerative Colitis Activity Index ; SAP = statistical analysis plan; 
UC = ulcerativ e colitis . 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 43 
LY3074828  5. Study Design  
5.1. Overall  Design  
Study AMBU  is a multicenter, open -label PK study  designed to  evaluate the safety, PK, 
pharmacodynamic s (PD), and clinical response of mirikizumab in pediatric patients, and to 
provide data for dose confirmation for  Phas e 3.   
The study population includes patients with moderately to severely active UC who have an 
inadequate response to, loss of response to, or are intolerant to non -biologic therapy for UC 
(biologic -naive ), and /or those who have been exposed to at least 1 biologic  and/or JAK inhibitor  
therapy for UC (biologic /JAK inhibitor -experienced ).  
Patients weighing >40 kg will receive a mirikizumab induction dose of 300 mg via IV infusion 
and patients weighing ≤ 40 kg will receive  induction doses of  5 or 10 mg/kg via IV infusion at 
Weeks 0, 4 , and 8 .  Enrollment will begin with  the 300 mg and 5 mg/kg dose cohorts.  Patients in 
the 10 mg/kg cohort will be enrolled after 5 patients in the 5 mg/kg dose cohort have received 4 
weeks of  mirikizumab , an evaluation of the available PK in the 5 mg/kg cohort (as described in 
Section 10.3.8.1 ) has been conducted , and enrollment of the 5 mg/kg dose cohort has been filled . 
Patients who achieve a Modified Mayo Score (MMS) clinical response ( see Table  AMB U.5) at 
Week 12 will proceed to the maintenance period and receive SC doses of 200 mg (weight > 40 
kg), or 100 mg (weight >20 kg to ≤40 kg), or 50 mg (weight ≤20 kg) mirikizumab Q4W  through 
Week 48.  
Patients who do not meet the MMS clinical response definition at Week 12 may receive 
extended IV induction dosing (either at the same dose or for the 5 mg/kg dose cohort, escalate to 
the 10 mg/kg  dose) for 12 more weeks  or discontinue .  Following the completion of IV dosing  at 
Week 24 , if the investigator determines that the patient has improved, the patient will proceed to 
the maintenance period and receive Q4W SC doses based on weight  class through Week 48.   If 
the investigator determines that  sufficient improvement was not made, the patient will 
discontinue study drug and undergo procedures for early termination of the study drug, including 
post-treatment follow -up as described in the Schedule of Activities (Section 2).   
Upon completion of the maintenance period (Week 52) , all patients will have the option to enter 
the 3-year long-term extension Study I6T -MC-AMAZ (AMAZ)  or enter the post -treatment 
follow -up period  (12 weeks following SC administration ).  With sponsor approval, additional 
dosing at Week 52 and unscheduled visits (UV) beyond Week 52 may occur as needed for 
patients eligible to enroll in Study AMAZ where the clinical trial site is not yet open. Patients 
must have completed all procedures at Visit 16 and additional dosing should occur at 4 -week 
intervals ( ±7 days) from the prior dose.  Patients wh o discontinue while receiving IV dosing will 
undergo procedures for early termination of the study drug, including post-treatment follow -up 
for 16 weeks as described in the Schedule of Activities (Section 2).   
Figure  AMB U.1 illustrates the study design   
Study governance considerations are d escribed in detail in Appendix 3 . 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 44 
LY3074828    
Figure  AMB U.1. Illustration of study design for clinical p rotocol I6T-MC-AMB U.
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 45 
LY3074828  5.1.1.  Definition of Baseline  
Visit 2 (Week 0) is the baseline visit.  The baseline MMS  is calculated from valid  diary 
entries obtained prior to endoscopy during the screening period and the endoscopic appearance 
of the mucosa at this screening endoscopy (Section 9.1.1 ).  For other efficacy, health outcomes, 
and safety assessments, baseline is defined as the last non -missing assessment recorded on or 
prior to the date of Visit 2 (Week 0).  
5.1.2.  Definition of Enrollment  
A patient is consider ed enrolled in the study once the patient is assigned to treatment.  
5.2. Number of Participants  
Approximately 60 patients with moderately to severely active UC will be screened to enroll 
approximately  30 patients . 
5.3. End of Study  Definition  
End of the study  is the date of the last visit or last scheduled procedure as shown in the Schedule 
of Activities  (Section 2) for the last patient.  
5.4. Scientific Ratio nale for Study Design  
Study AMB U is an open -label , Phase 2 study to evaluate the safety, PK, PD, and clinical 
response of mirikizumab  in pediatric  patients  with UC , to provide data for dose regimen 
confirmation  in Phase  3. 
An open -label study ensures that all patients receive active treatment while allowing  the primary 
evaluation of PK  of mirikizumab treatment in pediatric patients . 
The 12 -week IV dosing induction period was chosen  
 The 40 -week maintenance period enab les 
  The timing of the induction and 
maintenance endpoints was chosen based on  characterization of th e safety and efficacy of 
mirikizumab through 52 weeks of continuous treatment in Study AMAC, the Phase 2, 
placebo -controlled, double -blind adult clinical trial of mirikizumab in m oderately to severely 
active UC , as well as consistency with the timing of th e induction and  maintenance endpoints of 
the ongoing  Phase 3 adult program  studies AMAN  and AMBG .  
Patients are allowed to continue non -biologic background therapy throughout the study (for 
example, 5-aminosalicylic acids  [5-ASAs ], corticosteroids, AZAs, and 6 -MPs), subject to 
concomitant medication and dose stabilization criteria.  In this context, it is anticipated that 
mirikizumab  will be administered as an add -on therapy in the majority of patients.   
The selection of clinical remission at Week 52 usin g MMS  (FDA 2016) and the Pediatric 
Ulcerative Colitis Activity Index (PUCAI ) as secondary endpoint s are consistent with regulatory 
guidance documents (EMA  2016a,b).  These endpoints will assess improvement in the clinical 
signs and symptoms of stool freque ncy (SF), rectal bleeding (RB) , and abdominal pain, and 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 46 
LY3074828  additionally assess the visual appearance of the mucosa through the endoscop ic subscore (ES).  
 
 
5.5. Justification for Dose  
Dose regimens and weight categories are based on analyses of PK, exposure –response, a nd 
safety data from the Phase 2 adult study  AMAC  in patients with UC.   Study AMAC evaluated 
mirikizumab IV induction doses of 50, 200, and 600  mg administered Q4W and SC maintenance 
doses of 200  mg administered Q12W  or Q4W.  The 50  mg and 200  mg IV induction dose 
cohorts included exposure -based dose adjustments that resulted in overall average induction 
doses of 100 and 250  mg, respectively.   Evaluation of unblinded  safety data from the completed 
and ongoing clinical studies, which assessed mirikizum ab doses up to 10 00 mg  IV Q4W,  
demonstrate an acceptable safety profile to date .  Based on data from Study  AMAC, the doses 
selected for evaluation in adults in Phase 3 are 300  mg IV Q4W during induction and 200  mg SC 
Q4W during maintenance.  
Previous evalua tions of therapeutic antibodies in pediatric subjects  indicate  that the primary 
factor that influences PK is body weight rather than age ( Dirks and Meibohm 2010 ).  The range 
of adult body weights in Study AMAC was 40 to 122 kg, with a median of 75  kg.  Although 
there was a trend for decreasing mirikizumab clearance with decreasing body weight in Study 
AMAC, this relationship was not statistically significant .  However, for the purposes of initial 
dose selection for this study , an allometric relationship bet ween body weight and mirikizumab 
clearance with an exponent of 0.8 was assumed.  This allometric relationship provides a more 
conservatively high estimate of exposure for a given body weight as compared  to assuming no 
relationship, and also is consistent w ith historical data for other therapeutic antibodies ( Bai et al. 
2012 ). 
Based on Study  AMAC adult data and the  
 
  Therefore, evaluation of an IV dose of 300  mg is planned for the induction period of the 
study for patient s with a body weight >40  kg.  This dose i s expected to provide comparable 
induction exposures as the 300 mg IV Q4W that is being evaluated in Phase 3 adult studies.  
Pediatric patients with a body weight of ≤40 kg will receive doses using a weight -based 
approach (mg/kg) that is expected to provide  comparable  systemic exposu res as doses evaluated 
in the adult Phase 2 study AMAC  and in Phase 3 .  Intravenous d oses of 5  and 10 mg/kg are 
planned for the induction period for patients with a body weight of ≤40 kg  to collect sufficient 
PK data over a dose range of interest and optimally support the selection of an induction dose  in 
future studies  that will produce exposures similar to adults . 
Figure AMB U.2 shows a comparison of the exposures projected  for the weight -based doses 
relative to the 300  mg IV planned for adults in Phase 3 and the 600  mg IV dose evaluated in 
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 47 
LY3074828  Study AMAC.   The planned weight -based doses are not expected to produce exposures higher 
than those evaluated in the adult Phase 2 study.  
Interim and/or real -time analyses of PK data from pediatric patients  that receive the lowest 
induction doses in this study (300 mg and 5 mg/kg) will be conducted prior to enrolling the 
10mg/kg  cohort, as shown above in Figure  AMB U.1.  The 10 mg/kg dose level  may be adjusted 
based on these analyses, but it will be no higher than the 10 mg/kg currently planned.  
Figure AMB U.2. Comparison of interquartile range for average induction 
concentration for the doses planned in pediatric patients ≤40 kg  
relative to adults.  
The dose  regimen  selected for the maintenance period of the study for patien ts with a body 
weight of >40  kg is 200 mg SC Q4W , and this dose is expected to provide comparable 
maintenance exposures to the 200  mg SC Q4W that is being evaluated in Phase 3 adult studies.  
The maintenance dose regimens for patients ≤40 kg  are divided into 2 fixed SC doses based on 
body weight.  Patients with a body weight between >20 kg and ≤40 kg  will receive a  100 mg SC 
Q4W dose, and patients with a body weight ≤2 0 kg will receive a  50 mg SC Q4W dose .  
Figure  AMB U.3 shows a comparison of the exposures projected for these dose regimens relative 
to the 200  mg SC Q4W maintenance regimen planned  for adults in Phase  3.  The planned SC 
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 48 
LY3074828  maintenance doses are expected to produce exposures similar to the 200  mg SC maintenance 
dose that was evaluated in the adult Phase 2 study.  
Figure  AMB U.3. Comparison of interquartile range for average  maintenance 
concentration for the doses planned in pediatric patients relative to 
adults.  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 49 
LY3074828  6. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted.   A patient is considered enrolled into the  
study once the patient is as signed to treatment.  
6.1. Inclusion Criteria  
Patients  are eligible to be included in the study only if they meet all of the following  criteria 
within the screening period, which is , unless otherwise 
specified below : 
Informed Consent  
[1] Have given assent (if appropriate) with parent/legal guardian signed informed 
consent approved by the ethical review board (ERB) governing the sit e. 
Patient  Characteristics  
[2] Male or female patients weighing >10 kg AND ≥2 and <18 years of age at the 
time of informed consent .  
[2a]  
 
 
[2b] 
 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 50 
LY3074828  [3] Both the parent or legal representative and child (if capable) must agree to 
comply with the requirements of the protocol .  
[4] 
Type of Patient  and Disease Characteristics  
[5] Have an established diagnosis of UC of ≥3 months in duration before 
baseline,   
  
[6] Have moderately  to severely active UC as defined by a  
 within  before first dose of study treatment ( baseline ). 
[7] Have evidence of UC extending proximal to the rectum  
 
Prior Medication Failure Criteria  
[8] Patients must have an inadequate response to, loss of response to, or 
intolerance to at least 1 of the me dications described in Criteria  [8a] OR [8b].  
Documentation of dose, frequency, route of administration , and duration 
of the prior failed treatment is required .   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 51 
LY3074828  [8a] Biologic -naive  patients:   Patients who have an inadequate response to, 
loss of response to, or are intolerant  to at least 1 of the following 
medications:   
 Corticosteroids   
o Corticosteroid -refractory colitis, defined as signs and/or symptoms of 
active UC despite a
 Immunomodulators : 
o Signs and /or symptoms of persistently active disease despite at least 3 
mont hs’ treatment with 1 of the following:  
 Oral AZA  or 6-MP , or 
 
o History of intolerance to at least 1 immunomodulator  
 
Discontinuation despite clinical benefit does not qualify as having failed or being 
intolerant to UC non -biologic therapy.  
[8b] Biologic /JAK inhibitor -experienced  patients:   Patients who have an 
inadequate response to,  to biologic 
therapy for UC  (such as anti-TNF antibodies or  anti-  antibodies ) 
and/or to JAK inhibitors (such as tofacitinib) , as des cribed below .  
Investigators must document an adequate trial of the medication .  
Patients should fulfill at least 1 of the following criteria:    
  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 52 
LY3074828   Inadequate response:  S igns and symptoms  of persistently active disease 
despite prescribed induction treatmen t, or 
  
 Intolerance:  H istory of  intolerance  to infliximab, adalimumab, golimumab , 
vedolizumab , tofacitinib , or other biologics or JAK inhibitors  (including but 
not limited to infusion -related event , demyelination, congestive heart failure, or 
any other drug -related AE that led to a reduction in dose or discontinuation of 
the medic ation ), or 
Dose Stabilization Inclusion Criteria  
[9] Are on s table doses of the following  permitted  drugs  (see Appendix 6 ): 
[9a] Oral 5 -ASA compounds:  if the prescribed dose has been stable for  
 before screening endoscopy . 
[9b] Oral corticosteroid therapy  
:  if the prescribed dose has been  
before the screening endoscopy .  
[9c]  have been prescribed 
at a stable dose for at least  before the screening endosc opy.  
Study Procedure Inclusion Criteria  
[10] Are willing and able to complete the scheduled study assessments, including 
endoscopy , and  diary entry . 
[11] Have clinically acceptable central laboratory results or local laboratory results  
reviewed and approved by sponsor medical  monitor  or designee  during 
screening, as assessed by the investigator, including:  
  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 53 
LY3074828  [11a] Hematolog y:   
[11b] Chemistry:   
o  may be allowed to enroll but cases 
must be discussed and judged not clinically significant by the sponsor 
medical monitor  prior to enrollment . 
 Patients with 
 
Retesting within the screening period is allowed for hematology and chemistry; 
see Section  6.4. 
[12] Are  
guidelines  as noted by country specific pediatric authorities ( for example,  the 
American Academy of Pediatrics).   
 
6.2. Exclusion Criteria  
Patients will be excluded from study enrollment if they meet any of the following criteria within 
the screening period, which is  to the start of study  drug, unless otherwise 
specified below : 
For rescreening activities within the screening period, see Section  6.4. 
Gastrointestinal Exc lusion Criteria  
[13] Have a current diagnosis of  CD, IBD-Unclassified (formerly known as 
indeterminate colitis) , ulcerative proctitis (distal disease limited to the 
rectum ), or primary sclerosing cholangitis . 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 54 
LY3074828  [14] Have a documented history of   
 
[15] Previous bowel resection or intestinal or intra -abdominal surgery:  
 Have had any small bowel or colonic surgery within  prior to 
baseline . 
 Have had any non -intestinal intra -abdominal surgery within  of 
baseline . 
[16] Have evidence of toxic megacolon,  
 the small bowel or colon . 
[17] Have any history or current evidence of cancer of the gastrointestinal tract .  
Criteria for Discontinuing Prohibited Medications  
[19] Have received any of the following for treatment of UC within the timeframes 
specified below:   
[19a] Corticosteroid enemas, corticosteroid suppositories , or IV corticosteroids 
 prior to screening endoscopy . 
[19b] 5-ASA enemas or 5 -ASA suppositories  prior to screening 
endoscopy . 
[19c]
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 55 
LY3074828  [19d] Anti-TNF antibodies ( for example,  infliximab, adalimumab , or 
golimumab) within  prior to screening endoscopy . 
[19e] 
[19f] 
[19g] Any investigationa l therapy (biologic or non -biologic) within  
 
prior to the screening endoscopy or within 5 half -lives prior to 
the screening endoscopy, whichever is longer .   
[19h]  
 
[19i]  
[20] Have failed  anti-IL12p40 antibodies ( for example,  ustekinumab 
[STELARA ®]) or  have ever received anti-IL-23p19 antibodies ( for example,  
risankizumab [BI -655066 /ABBV -006], brazikumab [MEDI -2070], 
guselku mab [CNTO1959], or tildrakizumab [MK -3222]) for any indication, 
including investigational use . 
Infect ious Disease Exclusion Criteria  
[21] Patients who : 
[21a]  Have evidence of active  TB, or 
[21b]  Have a past history of active TB, regardless of treatment, or  
[21c] Have a past history of latent tuberculosis infection ( LTBI ) and have not 
completed an appropriate TB treatment  regimen (Section  9.4.5.2 ) or 
[21d]  Are diagnosed with LTBI at screening .  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 56 
LY3074828  [22] 
[23] Have human immunodeficiency virus  (HIV)/acquired immunodeficiency 
syndrome ( AIDS ), test positive for HIV antibodies at screening  (see 
Section  6.2.1 ). 
[24] Have acute or chronic hepatitis B  infection  or test positive for hepatitis B 
virus (HBV) at screening, defined as:  
[24a] Positive for hepatitis B surface antigen  (HBsAg +). 
OR 
[24b] Positive for anti -hepatitis B core antibody ( anti-HBc+) and positive 
confirmatory PCR for HBV  deoxyribonucleic acid ( DNA ) (see Section  
9.4.5.4 ). 
OR 
[24c]  Detectable HBV DNA (see Section  9.4.5.4 ). 
[25] Have current hepatitis C infection , or test positive for hepatitis C virus (HCV) 
at screening, defined as:   
 Positive for hepatitis C antibody and detectable HCV ribonucleic acid 
(RNA ) (see Section 9.4.5.5 ). 
 
 
[26] Had Clostridium difficile  or other intestinal infection within  of 
screening endoscopy, or test positive at screening for C. difficile  or for other 
intestinal pathogens. 
 
[27] Have a current or recent acute, active nonserious extraintestinal infection for 
which signs and/or symptoms are present or treatment, if indicated, is not yet 
complete  prior to screening . 
[28] Patients with  serious, opportunistic or chronic/recurring extraintestinal 
infections should be adequately treated and off antibiotics for  without 
recurrence of symptoms prior to screening.  Serious extraintestinal infections 
include  but are not limited to the following : 
[28a] Infections requir ing IV antib iotics . 
[28b] Infections requiring hospitalization . 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 57 
LY3074828  [28c] Infections that are considered “opportunistic” (examples are listed in  
Appendix 9 ).  
[28d] Chronic, recurrent infections ( for example,  osteomyelitis and recurring 
cellulitis) .  
Patients with a n opportunistic infection or chronic, recurrent infection  
 should be discussed on a case -by-case basis with the medical monitor.    
[29] Have evidence of active/infectious herpes zoster infection or primary varicella 
zoster infection  prior to screening .  Infections are considered  active 
until all vesicles are crusted over.  
General Exclu sion Criteria  
[30] Have had lymphoma, leukemia, or any malignancy within  of 
screening .  
Exceptions:  The following conditions are not exclusionary:   
a) Basal cell or squamous epithelial carcinoma of the skin that has been adequately 
treated with no evidence of metastatic disease for  at least  
b) Cervical carcinoma in situ that has been adequately treated with no evidence of 
recurrence within  of baseline.  
[31] Are investigator site personnel directly affiliated with this study and/or their 
immediate families.  Immediate family  is defined as a spouse, parent, child, or 
sibling, whether biological or legally adopted . 
[32] Are Eli Lilly and Company ( Lilly ) employees or employees of third -party 
organizations involved with the study . 
[33] Are currently enrolled in any other clinical  study involving an investigational 
product or any other type of medical research judged not to be scientifically or 
medically compatible with this study . 
[34] Have previously completed or withdrawn from this study or any other study 
investigating mirikizu mab after receiving study drug .  This criterion does not 
apply to patients undergoing rescreening procedures . 
[35] Have had extra -abdominal surgery and have not recovered fully following 
surgery, including complete wound healing, before screening.   
[36] Have p resence of significant uncontrolled neuropsychiatric disorder or judged 
at risk of suicide in the opinion of the investigator;  
OR 
For patients  
during the screening 
period prior to dosing at Visit 2;  
OR 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 58 
LY3074828   
AND  
 
[37] Have an unstable or uncontrolled illness, including but not limited to a 
cardiovascular, respiratory, gastrointestinal (excluding UC), neurological or 
neuropsychiatric disorders, that would potentially affect patient safety within 
the study or confound efficacy assessment . 
[38] Have a known hypersensitivity to any component of mirikizumab or 
monoclonal antibodies . 
[39] Have a solid organ transplant or hematopoietic stem cell transplantation .  
[40] Are unwilling or unable to comply with the use of a data collection device to 
directly record data from the subject . 
[41] Are unsuitable for inclusion in the study in the opinion of the investigator or 
sponsor for any reason that may compromise the subject’s safety or confound 
data interpretation . 
[42] Are pregnant, lactating, or plan ning pregnancy (both males  and females ) while 
enrolled in the study or within  
 after receiving the last dose of study drug. 
[43] Have current or history of alcohol dependence and/or illicit drug abuse within the last 
year. 
[44] Have abnormal 12 -lead electrocardiogram ( ECG ) that, in the opinion of the 
investigator or sponsor, increases the risks associated with participating in the study . 
[45] Use marijuana (both recreational and medicinal uses including  cannabidiol [CBD ] 
oil]).  Marijuana use must be stopped prior to screening and is prohibited for the 
duration of the study.  
[46] Had a blood transfusion in the last  prior to hematology blood  sample 
collection .  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 59 
LY3074828  6.2.1.  Rationale for Exclusion of Certain Study Candidates  
Children younger than 2 years of age are excluded from this study due to the difficulty in 
obtaining a definitive diagnosis of UC in children/infants younger than 2  years of age and the 
potential for lack of efficacy in this age group .   
6.3. Lifestyle Restrictions  
If applicabl e, study participants should be instructed not to donate blood or blood products 
during the study or for  following their last dose .  In order to participate in the study, 
patients must agree to the contraception, reproduction, and breastfeeding criteria detailed in 
study entry criteria (Section 6.1 and Section 6.2). 
6.4. Screen Failures  
Allowed rescreening of patients  after initial screen failure  
Patients who have failed screening becau se of  the following Inclusion/ Exclusion Criteria may be 
rescreened  when the reason for screen failure has resolved :   
 [5] 
 [6] 
 [7] 
 [8] 
 [9] 
 [11] 
 [12] 
 [15] 
 [18c] (once polyps have been removed ) 
 [19] 
 [22] 
 [27] to [30] 
 [35]  
 [42] 
 [45], and 
 [46].  
Individuals may  be rescreened up to 2 times, for a maximum total of 3 screens  unless additional 
rescreening is approved  via sponsor’s medical monitor  or designee .   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 60 
LY3074828  Participants who have failed screening because of Exclusion Criterion [ 21c]  
 may be rescreened 1 time 
(see Section  9.4.5.2 ). 
Participants who have failed screening because of Exclusion Criterion [ 26] may be rescreened 
1 time for C. difficile  stool toxin.  Additionally, a participant may be rescreened 1 time for stool 
culture or ova parasite.  In either situation, participant res creening should only occur after the 
reason for screen failure has resolved.  It is recommended that the investigator confirms the 
participant has a negative C. difficile  stool toxin/stool culture/stool ova parasite (as applicable) 
before performing additi onal rescreening investigations (see also Section  9.4.5.7 ).  The interval 
between rescreening  visits should be at  unless a shorter interval has been agreed 
with the study’s medical monitor.  Each time rescreening is performed the participant, 
parent/guardian must sign a new informed consent form (ICF) and will be assigned a new 
identification number.  
Participants who screen fail because they are unable to complete their endoscopy prior to Visit  2 
will n ot be required to undergo repeat TB testing, chest X -ray (CXR) or computed tomography 
(CT), HIV, HBV, and HCV testing stool cultures, and C. difficile  testing if these were normal or 
negative during screening  after discussion with sponsor medical monitor o r designee .  These 
tests should be repeated if based on the investigator’s judgment the patient has risk factors and/or 
signs and symptoms of illness.  Participants may undergo repeat rescreening sooner than
between screen failure and rescreening.  
Disallowed rescreening of patients  after initial screen failure  
Patients who have failed screening because of  the following Exclusion Criteria may not be 
rescreened:   
 [10] 
 [13] 
 [14] 
 [16] 
 [18a] and [18b] 
 [20] 
 [21a] and [21b] (if current or past history of active TB)  
 [23] to [25]  
 [31] to [34]  
 [36] to [4 1] 
 [43], and  
 [44]. 
6.4.1.  Allowed Retesting of Screening Investigations  
The screening investigations specified below may be retested once without the need for 
rescreening at the discretion of the investigator.   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 61 
LY3074828   Screening hematology and chemistry blood tests:  where 1 or more results are outside 
the acceptable range for inclusion in the study but may be within the acceptable range for 
inclusion on retest ing, due to test -retest variability .   
 Stool testing :  if the re is a technical difficulty in performing or reporting the C. difficile  
or stool culture assays.  
 Retesting or confirmatory testing with an interferon -γ release assay (IGRA ):  for 
example, QuantiFERON ®-TB Gold  or T-SPOT ® assay ) in selected patients as part  of 
screening for LTBI (see Section  9.4.5.2  for details ).   
 Endoscopy :  where the endoscopist is unable to adequately visualize the mucosa ( for 
example,  due to poor bowel preparation, technical issues with equipment) or where the 
central reader is unable to determine  the centrally read Mayo ES (for example,  failure of 
the recording equipment ). 
Retesting of all other screening investigations should  be discussed with the medical monitor 
prior to retesting.  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 62 
LY3074828  7. Treatment s 
7.1. Treatments Administered  
In this study , mirikizumab  is administered  by IV or SC routes to pediatric patients  in a staggered 
approach based on dose level  as per Table  AMB U.3.  Assignment to weight classes will be based 
on body weight at enrollment  for induction period dosing  and Week 12  for dosing at Week 12 
and beyond; patients will continue in the assigned weig ht group throughout the duration of the 
study . 
Patients in the high weight cohort will receive flat dosing , while patients in the low weight 
cohort will receive weight -tiered dosing in order  to obtain similar exposures as flat dose 
regimens in the high er weight cohort.  
Patients who achieve clinical response at Week 12 will follow the treatment regimens described 
in Table  AMB U.3.  Patients who do not achieve clinical response at Week 12 will follow the 
treatment regimens described in Table  AMB U.4.   
If any patient experiences loss of response and meets the criteria for loss of response in 
Section  9.1.5  at or after Week 1 6 and up to Week 40 , they may receive rescue or discontinue  the 
study based on their physician’s discretion.  Rescue treatment is IV mirikizumab  Q4W  for 
3 doses based on their weight cohort.  Once IV loss of response  dosing is complete, patients who, 
in the opinion of the investigator, are receiving clinical benefit from mirikizumab therapy may 
continue with further SC dosing.   Patients who are not considered by the investigator to be 
receiving clinical benefit from mirikizumab IV rescue therapy, will be discontinued and proceed 
to post-treatment foll ow-up. 
Table  AMB U.3. Treatment Regimens :  Week 12  Clinical Responders   
Weight 
Cohort  Dose  
Weeks 0, 4, and 8  Dose  
Weeks 12 through 48  
Enrollment Initiation  
>40 kg  300 mg mirikizumab IV  200 mg mirikizumab Q4W SC  
≤40 kg  5 mg/kg  mirikizumab IV  ≤20 kg:  50 mg  mirikizumab Q4W SC  
>20 to ≤40 kg:  100 mg mirikizumab 
Q4W SC   
 
≤40 kg  10 mg/kg  mirikizumab 
IV ≤20 kg:  50 mg  mirikizumab Q4W SC  
>20 to ≤40 kg:  100 mg  mirikizumab 
Q4W SC  
Abbreviations:  IV = intravenous; PK = pharmacokinetics ; Q4W = every 4 weeks; SC = subcutaneous.  
 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 63 
LY3074828  Table  AMB U.4. Treatment  Regimens :  Week 12  Clinical Nonresponders  
Weight 
Cohort  Dose  
Weeks 0, 4, and 8  Dose  
Weeks 12 through 48  
>40 kg  300 mg mirikizumab IV  
≤40 kg  5 mg/kg  mirikizumab IV  
≤40 kg  10 mg/kg  mirikizumab IV  
Abbreviations:  IV = intravenous; Q4W = every 4 weeks; SC = subcutaneous.  
 
Study Drug Administration   
Intravenous  infusion of mirikizumab  will occur over at  
  All patient s should be monitored for  or longer following IV 
administration , according to investigator practice or local standard of care .  Sites must have 
resuscitation equipment, emergency medications, and appropriately trained staff available during 
the infu sion and monitoring period.   Detailed instructions for investigational product 
administration will be provided  separately  by the sponsor .    
Subcutaneous  administration of mirikizumab  will be given .  
Patients should be monitored according to investigator practice or local standard of care .  
Acceptable locations for SC administration include the abdomen, front upper thighs , upper arms , 
and buttocks . 
The investigator or his/her designee is responsible fo r the following:  
 Explaining the correct use of the investigational agent to the site personnel   
 Verifying that instructions are followed properly  
 Maintaining accurate records of investigational product dispensing and collection  
 At the end of the study retu rning all unused medication to Lilly, or its designee, 
unless the sponsor and sites have agreed that all unused medication is to be 
destroyed by the site, as allowed by local law  
7.1.1.  Packaging and Labelling  
Mirikizumab  will be supplied to the investigator by L illy or its designee.   Clinical trial materials 
will be labeled according to the country’s regulatory requirements.  All investigational products 
will be stored, inventoried, reconciled, and destroyed according to applicable regulations.   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 64 
LY3074828  Clinical trial materials are manufactured in accordance with current Good M anufacturing 
Practices  (GMP) . 
Study drug will be supplied as:  
 Single use solution pre -filled syringe containing mirikizumab .  The  syringe of 
mirikizumab  is manufactured to deliver    
 Single use solution vial containing mirikizumab .  The  vial of mirikizumab  is 
manufactured to  deliver     
Study drug will be provided with study -specific labels.   Syringes and vials will be supplied in 
cartons, with th e appropriate quantity specific to the planned dispensing schedule of the 
investigational product.   
7.2. Method of Treatment Assignment  
Study AMB U is open -label and patients will be assigned  to mirikizumab  dose groups based on 
weight  at Visit 2 .   
An interactive web -response system (IWRS)  will be used to assign investigational product to 
each patient.  Site personnel will confirm that they have located the correct investigational 
product package by entering a confirmation number found on the package in to the IWRS.  
At Week 12 , patients  who meet the clinical response  criteria (see Table  AMB U.5) may proceed 
to the maintenance period and will continue with open-label mirikizumab  SC dosing  based on 
current body weight . 
Nonresponding patients (see Section 9.1.5 ) may enter into extended induction dosing  via IV 
administration for the next 12 weeks  or discontinue the study .   
7.2.1.  Selection and Timing of Doses  
Patients  who meet all criteria will be assigned  to treatment and will receive their assigned study 
drug as outlined in Sections 7.1 and 7.2.  The actual time of all dose administrations will be 
recorded in the patient’s electronic case report form (eCRF).   
7.3. Blinding  
This is an open -label study.  
7.4. Dosage Modification  
Dose adjustments, other than  
 
, are not permitted in this study.   
7.5. Preparation/Handling/Storage/Accountability  
The investigator or his/her designee is responsible for the following:  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 65 
LY3074828   Confirming that appropriate temperature conditions have been maintained during 
transit for all study drug received and any discrepancies are reported and resolved 
before use of the study drug. 
 Ensuring that only participants enrolled in the study may receive study drug and 
only authorized site staff may supply or administer study drug.  All study drugs 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the  investigator and authorized site staff . 
 The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study drug accountability, reconciliation, and record 
maintenance (such as receipt, reconciliation , and fin al disposition records).  
Mirikizumab will be supplied by Lilly or its designee , in accordance with current GMP  and will 
be supplied with lot numbers, expiry dates, and certificates of analysis, as applicable.  
Mirikizumab  should be stored in refrigerated co nditions . 
Detailed instructions regarding supplies , preparation , and handling of mirikizumab  will be 
provided by the sponsor.   
7.6. Treatment Compliance  
All doses of study medication will be administered at the study site by site personnel.  Deviations 
from the prescribed dosage regimen should be recorded in the eCRF.  
Every attempt will be made to select patients and caregivers who have the ability to unde rstand 
and comply with study instructions.  The investigator is responsible for discussing methods to 
ensure high treatment compliance with the patient and caregiver before study enrollment .   
In particular, the investigator is responsible for ensuring tha t study participants and caregivers 
receive adequate training on and appropriate understanding of : 
 the review of caregiver remission SF value as a critical data point  
 how to evaluate their UC symptoms and to re cord them on the  d iary, and  
 the importan ce of b eing compliant with the  d iary recording.  
If a patient is noncompliant with study procedures and/or investigational product administration, 
the investigator should assess the patient to determine the reason for noncompliance and educate 
and/or manage the patient as appropriate to improve compliance.  Overall compliance with 
therapy is defined in the statistical analysis plan ( SAP).  If, in consultation with Lilly or its 
designee, the noncompliance is deemed to be significant or if further noncom pliance occurs, the 
patient may be discontinued from the study.  
7.7. Concomitant Therapy  
The list of prohibited medications and the list of permitted medications with dose stabilization 
guidance are provided in Appendix 5  and Appendix 6 , respectively.  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 66 
LY3074828  All concomitant medications  (including medicatio ns for bowel preparations)  taken during the 
study must be recorded in the Concomitant Medication eCRF.  This includes concomitant 
medications for UC as well as for underlying conditions or diseases, and for  AEs.  All patients  
are encouraged to  maintain the ir usual medication regimens for concomitant conditions or 
diseases throughout the study , unless those medications are specifically excluded  (Appendix 5 ).   
Stable doses of  permitted  UC concomitant medications  (other than oral corticosteroids) are 
encouraged , unless  dose modification  is required due to AEs,  or dose modification is otherwise 
specified in  Appendi x 6.  Patients taking  oral corticosteroids are to follow the corticosteroid 
taper instructions described in Section 7.7.1 .   
Administration of prohibited UC medications  for the management of symptoms of UC , approved 
or investigational, constitutes treatment failure.  Use of such medications should not be withheld 
if, in the opinion  of the investigator, failure to prescribe them would compromise patient safety.   
Patients  who require a prohibited medication to treat their UC (see Appendix 5 ) need to be  
discontinue d from study drug  and complete an early termination visit ( ETV ) and post -treatment 
follow -up visits.  
If a concomitant medication is needed to treat  an AE or for  appropriate medical management , the 
investiga tor should bas e decisions on  patient and clinical factors.   Local administration of 
corticosteroids (for example, intranasal, inhaled, intraarticular) are allowed as required for the 
management of pre -existing conditions and AEs.  A patient who initiates a prohibited me dication 
for a non -UC indication should be discussed with the medical monitor.  
Patients are allowed to continue or initiate any concomitant medication for non -UC conditions, 
diseases, or AEs, insofar that the medication is not specifically prohibited ( Appendix 5 ) and use 
of the medication complies with the dosing requirements as described in Appendix 6 . 
7.7.1.  Corticosteroid Taper  
The investigator should use clinical judgement of the benefit/risk of steroid tapering for each 
individual subject as corticosteroids should be tapered as soon as possible followi ng the 
recommended tapering regimen per local practice.   Patients who enter Study AMB U on 
corticosteroid therapy for treatment of UC  
 may initiate corticosteroid tapering 
based on the investigator ’s discretion .   who have not already 
begun tapering corticosteroid therapy should initiate corticosteroid tapering no later  than 
   with mirikizumab  will 
begin  is achieved  at any time after starting 
  
Symptomatic response is defined as at least a  from baseline in the composite 
clinical endpoint of the sum of SF and RB  subscores.  
The recommended tapering schedule for oral corticosteroids (other than budesonide) is 
as follows:  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 67 
LY3074828    In situations where the steroid tapering is 
paused , the tapering regimen (as described above ) should be reinitiated within  of 
interruption of taper  if possible , with a goal to compl ete tapering  
7.7.2.  Vaccine Administration During the Study  
Every effort should be made to vaccinate p atients with standard of care vaccines prior to entry in 
the trial.    
7.8. Treatm ent after the End of the Study  
7.8.1.  Study Extensions  
Patients  who complete this study through Week 52  and achieve clinical benefit  may be eligible 
to participate in Study AMAZ .  Patients who do not meet en rollment criteria for Study AMAZ  or 
do not opt to contin ue into Study AMAZ , will be asked to complete the post -treatment follow -up 
period, as described in the Schedule of Activities (Section  2), which will co mplete their study 
participation . 
7.8.2.  Treatment after Study Completion  
Mirikizumab  will not be made available to patients after conclusion of the study , except through 
enrollment in the long-term extension trial , Study AMAZ . 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 68 
LY3074828  7.8.3.  Special Treatment Considerations  
7.8.3.1.  Premedication for Infusions  
  Any premedication for 
infusions or injections should be discussed with the medical monitor.  Any premedication given 
should  be documented as a concomitant t herapy.  
Other Infusion -Related Events  
If a patient experiences a reaction consisting of  
during or up to 6 
 after an infusion of study drug, the following guidance should be followed:  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
C
C
I
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 69 
LY3074828  Injection Site Reactions  or Infusion Site Reactions  
If a patient experiences an injection site reaction  or an infusion site reaction , such as  pain, 
erythema, urticaria, pruritus , or angioedema localized to the SC injection  or infusion  site (in the 
absence of systemic hypersensitivity signs or symptoms), the following guidance should be 
followed:  
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 70 
LY3074828  8. Discontinuation Criteria  
8.1. Discontinuation from Study Drug  
8.1.1.  Permanent Discontinuation from Study Drug  
Study drug may be permanently discontinued during the study.  Patients who discont inue study 
drug early will undergo early termination procedures, which include an ETV and post -treatment 
follow -up visits.   
The investigator will also complete any AE reporting and follow -up that may be required (if 
applicable, see Section 9.2).   
If a patient ’s study drug is discontinued before the end of the study , the patient should complete  
the ETV and post-treatme nt follow -up period as follows:  
 Patients who discontinue investigational product  during  
 will return for post -treatment follow -up visits  
(Visit s 801 and 802)   after the end -of-treatment visit .  
 Patients who disco ntinue study drug  
will return for post -treatment follow -up 
visits (Visit s 801 and 802)   after the end -of-treatment visit.  
Possible reasons leading to permanent discontinuation of investigational product  include the 
following (list is not exhaustive) : 
Patient  Decision  
 The patient  or the patient’s designee, for example, parents or legal guardian , requests to 
discontinue investigational product.  
   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 71 
LY3074828  Disease Worsening   
 The patient requires rescue therapy for exacerbation of UC at  doses higher than those 
specified in the “dose stabilization” inclusion criterion (for example, prednisone 
 Inclusion Criterion [ 9]), or with medications specified in the “prohibited 
medications” exclusion criterion (for example, IV corticoster oids, infliximab, or IV 
cyclosporin e; Exclusion Criterion [ 19]) (see also  Appendix 5 ). 
Safety Criteria for Study Drug Discontinuation  
 The patient has a diagnosis of any of the following during the study:  
o Cancer other than squamous cell or basal cell carcinoma of the skin  
o Polypoid or non -polypoid dysplasia that is endo scopically visible or  invisible  
o Active TB ( see Section  9.4.5.2 ) 
o HIV/AIDS  
o Hepatitis B or development of detectable HBV DNA ( see Section 9.4.5.4 ) 
o Hepatitis C or development of detectable HCV RNA ( see Section 9.4.5.5 ). 
 The patient requires a colectomy during the study.  
 The patient has a systemic hypersensitivity event or anaphylaxis to mirikizumab 
(Section  7.8.3.2 ).  Study drug should be discontinued after a systemic hypersensitivity 
event or anaphylaxis . 
 The patient becomes pregnant.  Pregnant patients will not  undergo an endoscopy/ flexible 
sigmoidoscopy at the ETV.    
 The patie nt has absolute lymphocyte count  after retesting 
(see Section  8.1.2 ). 
 The patient is non -compliant with  LTBI treatment (see Section  9.4.5.2 ). 
 The patient experiences an AE or  SAE that , in the opinion of the investigator or sponsor,  
would preclude him/her from continuing to receive study drug  or if they experience 
disease worsening that requires rescue therapy with protocol excluded medications . 
Other Reasons for Study Drug Discontinuation  
 The investigator determines that the patient is repeatedly noncompli ant with study  
procedures and/or study drug  (see Section 7.6). 
 Inadvertent enrollment ( see Section  8.1.3 ). 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 72 
LY3074828  Patients d iscontinuing from the investi gational product prematurely for any reason should 
complete AE and other follow -up procedures per Section 2 (Schedule of Activities), Section 9.2 
(Adverse Events) , and Section 9.4 (Safety ). 
8.1.2.  Temporary Interruption (Withholding) of  Study Drug  
Some possible reasons for temporar ily withholding the investigational product include  (but are 
not limited to) : 
 Patient develop s C. difficile , or other clinically important intestinal or extraintestinal 
infection during the study  (including LTBI) , see Section 6.2. 
 Patient requir es major surgery (administration of the investigational product may be 
restarted only after adequate wound healing ). 
 Patient develops a confirmed  absolute neutrophil count  
 
 Patient develops absolute lymphocyte count  
 must be discontinued, if applicable, for a confirmed 
absolute lymphocyte count  (2 assessments below this threshold).   The 
hematology must be repeated in .   If the absolute lymphocyte count remains 
, the hematology will be repeated again in  ( that is , prior to the next 
dose of study drug).   If the absolute lymphocyte count remains , the next dose 
of study drug will not be administered.  The hematology will be repeated again in  
  If the absolute lymphocyte count remains , study drug will be 
permanently discontinued.  White blood ce ll and lymphocyte counts will be followed for 
these patients until they return to an acceptable level.  
 The patient has  other laboratory  abnormalities that may lead investigator  to hold  the 
study drug until resolution  of the abnormalities . 
Cases that may merit temporary withholding of the study drug should be discussed with the 
medical monitor.  The medical monitor, in consultation with the investigator, will determine 
when it is appropriate to recommence study drug.   
8.1.3.  Discontinuation of Ina dvertently Enrolled Patients  
If the sponsor or investigator identif ies a patient  who did not meet enrollment criteria and was 
inadvertently enrolled, then the patient should be discontinued from study drug, unless there are 
extenuating circumstances that m ake it medically appropriate  for the patient to continue on study 
drug.  If the investigator and the sponsor agree it is medically appropriate to continue, the 
investigator must obtain documented approval from the sponsor to allow the 
inadvertently -enrolle d patient to continue in the study with or without treatment with the 
investigational product.  Patients who are discontinued from study drug should have s afety  
follow -up as outlined in Section 2 (Schedule of Activities), Section 9.2 (Adverse Events), and 
Section 9.4 (Safety) , including ETV and post -treatment follow -up visits ( Visit 801 and 
Visit 802). 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 73 
LY3074828  8.2. Discontinuation from the Study  
Patients will be discontinued  (withdrawn) from the study  in the following circumstances:   
 Enrollment in any other clinical study involving an investigational product or 
enrollment in any other type of medical research judged not to be 
scientifically or medically compatible with this study  
 Participation in the study needs to be stopped for medical, safety, regulatory, 
or other reasons consistent with applicable laws, regulations, and good clinical 
practice s 
 Investigator decision  
o The investigator decides that the patient  should be disco ntinued  from the 
study  
o If the patient , for any reason, requires treatment with another  therapeutic 
agent that has been demonstrated to be effective for treatment of the study 
indication, discontinuation from the study will occur prior to introduction 
of the new agent  
o For patients who develop a condition , require a live vaccine,  or begin a 
therapy that would have excluded entry into the study, the investigator 
must  consult with Lilly -designated medical monitor to decide whether the 
patient can continue takin g study drug and remain in the study.  
 Patient  decision  
o The patient  or the patient’s designee, for example, parents or legal 
guardian  requests to be withdrawn from the study  
Patients d iscontinuing from the study prematurely for any reason should complete AE and other 
safety follow -up specified per ETV , as outlined in Section 2 (Schedule of Activities), Section 9.2 
(Adverse Events) , and Section 9.4 (Safety).  
8.3. Lost to Follow -Up 
A patient  will be considered lost to follow -up if he or she repeatedly fails to return for  scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make 
diligent attempts to contact patients who fail to return for a schedule d visit or are otherwise 
unable to be followed up by the site.  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 74 
LY3074828  9. Study Assessments and Procedures  
Section 2 lists the Schedule of Activities, with the study procedur es and their timing (including 
tolerance limits for timing).   Adherence to the study design requirements, including those 
specified in the S chedule of Activities , is essential and required for study conduct.  
Appendix 2  lists the laboratory tests that will be performed for this study.  
A summary of the maximum number and volume of invasive samples for all sampling during the 
study  will be provid ed separately . 
Unless otherwise stated in the subsections below, all samples collected for specified laboratory 
tests will be destroyed within  of receipt of confirmed test results.  Certain samples may 
be retained for a longer period, if necessary,  to comply with applicable laws, regulations, or 
laboratory certification standards.  
9.1. Efficacy Assessments  
Efficacy  endpoints are found in Table  AMBU .2.  Secondary efficacy e ndpoint definitions are 
found in Table  AMB U.5.  Additional details are provided below.  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 75 
LY3074828  Table  AMB U.5. Secondary Efficacy Endpoint Definitions in Study AM BU 
Endpoint  Definition  
Modified Mayo Score (MMS) 
clinical remission   Stool frequency (SF) subscore = 0, or SF = 1, and  
 Rectal bleeding (RB) subscore = 0; and 
 Endoscopic  subscore (ES) = 0 or 1 (excluding friability)  
MMS c linical response   A decrease in the MMS of ≥2 points and ≥30% decrease from 
baseline, and   
 A decrease of ≥1 point in the RB subscore from  baseline or a RB 
score of 0 or 1  
Corticosteroid -free remission  
without surgery  
Pediatric Ulcerative Colitis 
Activity Index (PUCAI) clinical 
remission   A PUCAI score of <10 points  
PUCAI clinical response   A reduction in baseline PUCAI score of ≥ 20 points  
Endoscopic remission   ES = 0 or 1 (excluding friability)  
Symptomatic remission   SF = 0, or SF =  1 with ≥1 -point decrease from baseline , and 
 RB = 0 
Histologic -endoscopic mucosal 
remission   Defined as achieving both  histologic  remission  and endoscopic  
remission .  Histologic remission  will be specified in the  statistical 
analysis plan  (SAP). 
Loss of clinical response   Week 12 responders:  An increase from the Week 12 Partial Mayo 
score of  (with 
confirmation of negative C. difficile  testing) or 
 Week 12 non responders who had extended induction:  An 
increase from the Week 2 4 Partial Mayo score of  
 (with confirmation of 
negative C. difficile  testing)  
Symptomatic response    from baseline in the composite clinical endpoint of 
the sum of SF and RB subscores  
9.1.1.  Mayo Score  
This study utilizes components and permutations of the Mayo score (Schroeder et al. 1987) to 
assess UC disease activity for the primary and secondary endpoints (see Appendix 7 ).  Complete 
and accurate recording of the Mayo SF and RB su bscores by patients  or their 
parent/caregiver in their daily  electronic diary is necessary for the success of the study .  
Adequate bowel preparation and an endoscopy wi th adequate visualization of the mucosa will 
enable calculation of the Mayo ES.   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 76 
LY3074828  Note:   The investigator is responsible for ensuring that study participants receive adequate 
training on and appropriate understanding of : 
 the importance of complete bowel preparation  prior to endo scopies /flexible 
sigmoidoscopies  
 how to record “remission/ normal” SF at the beginning of the study  
 how to evaluate their UC symptoms and to record them on the  diary, and  
 the importance of being compliant with the  diary  recording.  
The Mayo score is a composite instrument comprised of the following 4 subscores:  
Stool Frequency (SF):  The SF subscore is a patient -reported measure.  This item reports the 
number of stools in a , relative to the normal number of  stools for that patient in 
the same period, on a 4 -point scale (see Appendix 7 ). 
 
 The total number of stools passed  will be recorded by the 
patient or caregiver  in a daily electronic diary.  The reference “normal” SF for that patient wil l be 
recorded electronically at the screening visit.  Normal SF for that patient is based on reported SF 
when the patient was in remission or reported SF before initial onset of signs and symptoms of 
UC.  Study software will use the patient -reported daily SF and the reference normal SF to 
automatically calculate the Mayo SF subscore.  Further details on the analysis of  diary 
items are contained in the SAP.   
Rectal Bleeding (RB):   The RB subscore is a patient -reported measure.  This item reports the 
most severe amount of blood passed with stool for a given day, on a 4 -point scale (see Appendix 
7).  The patient  or caregiver  will record this in a  electronic diary.  
Endoscopic  Subscore (ES):  The ES is a physician -reported measure that reports the worst 
appearance of the mucosa on flexible sigmoidoscopy or colonoscopy, on a 4 -point scale (see 
Appendix 7 ).  Determination of the ES is further detailed in Section 9.1.2 .  Consistent with  
current clinical practice and regulatory advice, this study subscore excludes friability from the 
definition of an ES of 1.  Also consistent with best clinical trial practice, endoscopy scores will 
be determined from blinded central readers.  The  en doscopy score is collected on paper and 
) in the eCRF .  The entry 
of the local endoscopy is critical to initiate the blinded central reading process.  
Physician’s Global Assessment (PGA):   The Physician’s Global Assessment  (PGA ) is a 
physician -reported measure that summarizes the investigator’s assessment of the patient’s UC 
disease activity on a 4 -point scale (see Appendix 7 ).  The investigator will record the PGA 
electronically as source data in the tablet device at appropriate study visits.  Consistent with 
regulatory guidance, the PGA will not be used solely for efficacy assessment in this study.  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 77 
LY3074828  Each subscore is scored on a 4 -point scale, ranging from 0 to 3, to give a maximum Mayo score 
of 12.  The study will use the following permutation of the Mayo score:  
 Modified Mayo score (MMS) :  a sum of the Mayo SF, RB , and ES, giving a maximum 
MMS of 9  
 Partial Mayo score:  a sum of the Mayo SF, RB , and PGA, giving a maximum Partial 
Mayo score of 9 
Additional permutations of the Mayo score have been described and  may be used in analyzing 
data from this study.  
Observer -reported outcomes will be used in place of patient -reported outcomes for children less 
than 8 years of age.   To maintain consistency in reporting of SF and RB data, the patient ’s age at 
baseline will determine whether an observer -reported method (ages 2  through 7 years ) or a 
patient -reported method (ages 8 through 17  years ) will be used , irrespective of patient ’s age at 
later study visit s.  Efficacy assessments will be conducted in study population age range for 
which the scale/instrument was validated . 
9.1.2.  Endoscopy  
Endoscopy will be used to determine the Mayo ES at  
  Site and blinded central reading of endoscopies will be used to determine ES.  
A flexible sigmoidoscopy or colonoscopy will be performed on all patients  during screening, 
within  to Visit 2 .  The endoscopy report and histopathology report (if biopsies are 
sent to the local histopathology laboratory) must be available in the source documents.  Prior to 
performing the screening endoscopy, inves tigators should ensure that patients have SF and RB 
scores that suggest they will meet entry criteria (see Inclusion Criterion [6] ) and clinically 
acceptable laboratory test results, including stool tests that are “negative” for C. difficile  and 
other inte stinal pathogens (see Inclusion Criterion [ 11] and Exclusion Criteria [ 21] and [ 23] to 
[26]). 
Flexible sigmoidoscopy is generally recommended.  However, full colonoscopy may be 
appropriate in some patients ( for example,  those with mild-to-moderate pan -colitis).  The choice 
of flexible sigmoidoscopy or full colonoscopy is at the investigator’s discretion.  Other situations 
that may warrant a full colonoscopy at sc reening include : 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 78 
LY3074828  In these patients, the investigator can obtain additional biopsies to surveille for dysplasia 
at the screening c olonoscopy.  This screening colonoscopy will be performed according 
to local guidelines and biopsies will be sent to the local histopathology laboratory.  
Chromoendoscopy may be an acceptable method of targeting biopsies, if allowed 
according to local guid elines.   
 Patients requiring  screening for colorectal cancer, who do not have a current screening 
colonoscopy according to local guidelines.  This may include:  
o Personal history indicating increased colorectal cancer risk, for example, previous 
adenomatous polyps.  
o Patients with other known risk factor s. 
 Where, in the opinion of the investigator, a colonoscopy is indicated at screening, for 
example, to confirm that a recent removal of an adenomatous polyp is complete prior to 
study enrollment .   
 Patients who do not have the report of a completed, full colonoscopy available in source 
documents.  
Patients who undergo colonoscopy at screening do not require a separate flexible sigmoidoscopy.  
Patients will undergo a  
  The endoscopy report and histopathology report (if biopsies are sent to the local 
histopathology laboratory) must be available in the source documents.  Patients who discontinue 
the study drug because of pregnancy will not undergo a  flexible sigmoidoscopy  or full 
colonoscopy  at their ETV.  
The endoscopist will be a  
  Investigators may delegate endoscopy 
to other m embers of the study team.  However, all study staff performing endoscopy must 
 
 at each endoscopy an d it will be 
recorded in the eCRF.   
All endoscopic procedures will be video recorded using a storage medium provided by the 
sponsor or designee.  The video images will be sent for independent central reading.  An 
endoscopy video instruction manual  from th e central reading laboratory will outline the standard 
study procedures used to capture and transmit video recordings of endoscopic procedures 
throughout the study, and the qualifications required of the central reader.   
The central reader s will determine the centrally -read Mayo ES at each  
 in a blinded manner, as detailed in the image review charter.   
The procedure to address d isagreement between the site readers and central read ers is detailed in 
the image review charter.  The  final Mayo ES will be provided to the site  prior to being enrolled 
at Visit 2  to enable determination of the MMS for eligibility . 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 79 
LY3074828  9.1.3.  Endoscopic Biopsies  
A histopathology report supporting the diagnosis of UC must be  available in the source 
documents prior to study enrollment , in order t o satisfy Inclusion Criterion [5 ].  If a 
histopathology report is not available, the investigator can obtain additional biopsies for this 
purpose at the screening endoscopy (sent to th e local histopathology laboratory).   
Biopsies will be obtained at each endoscopy to support assessment of the histopathology 
endpoints in this study and , where permitted,  .  In 
rare circumstances, the investigat or may consider it unsafe to collect all required biopsies; in this 
situation, fewer biopsies may be collected so as not to jeopardize patient safety.  Biopsies will be 
sent to the central study laboratory for processing.  A detailed biopsy reference guide  from the 
central reading laboratory will provide the number of biopsies to be collected, and outline the 
procedures to be used for secure specimen transfer, processing, slide preparation, and digitization 
of slides for histopathologic scoring.  These resu lts will not be made available to study sites.   
9.1.4.  Pediatric Ulcerativ e Colitis Activity Index  
The PUCAI (Turner et al.  2007) is a clinician -administered, 6 -item questionnaire that measures:  
abdominal pain; RB; stool consistency; number of stools; nocturnal  stools; and activity level  (see 
Appendix 7 ).  All items are answered as an average over the ‘past 2 days’.  A total disease 
activity score is c alculated from 0  to 85, with severe :  65-85, moderate :  35-60, mild:  10-30, and 
none :  <10.  The clinician will record the patient or caregiver/legal guardian responses for the 
PUCAI electronically as source data in the tablet device  at appropriate visits.  
9.1.5.  Determination of Responder Status/Loss of Response  
At Week 12, patients who achieve  an MM S clinical response as defined in Table  AMB U.5 may 
move into the maintenance period .   
Week 12 Non responders are defined as those that do not meet  the following criteria:  
 A decrease in the MMS of  from baseline,  and 
 A decrease of  in the RB subscore from baseline or a RB score . 
Nonresponding patients may receive extended induction  dosing via IV infusion Q4W for 12 
weeks as noted in Table  AMB U.4. 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 80 
LY3074828  9.1.6.  Growth and Pubertal Assessments  
9.1.6.1.  Occipital Head Circumference  
Occipital head circumference measurements will be performed on patients less than  3 years  of 
age at baseline.  Measurements will be taken at baseline and then approximately Q12W  
thereafter , until the patient reaches the age of  3 years . 
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 81 
LY3074828  9.1.6.2.  Height Velocity  
Height will be collected 3 times per visit at the visits indicated  in Section 2 using a stadiometer  
or other instrument of equivalent measuring capacity .  Observed height velocity by gender and 
age group will be calculated at  , based on height 
measurements from the 3 to 12 months (preferably 4 to 6 months) preceding th e study (from 
screening ) or those obtained at baseline according to the following formula:  
 (Present Height [cm] - Previou s Height [cm])/Interval (months) Between Measurements 
× 12 
Age-specific z -scores for height velocity by gender and age group will be calculated for each 
patient with reference to standard height velocity tables according to the following formula:  
 (Observe d Height Velocity [cm/y] - Mean Height Velocity for Age and Sex 
[cm/y])/( Standard Deviation of the Mean)  
Full details on height velocity analyses can be found in the SAP.  
9.1.6.3.  Assessment of Puberty  
 
 
 
  The date of onset of menstruation will also be collected.  
9.1.7.  Health  Outcome s Instruments  
Observer -reported outcomes will be used in place of patient -reported outcomes for children less 
than  for the following scales .  The patient’s age at entry into the study w ill 
determine which scale/instrument is used and this will not change as the patient ages during the 
study.    
Abdominal Pain Numeric Rating Scale:   The abdominal pain numeric rating scale ( NRS ) is a 
single item that measures the “worst abdominal pain in the past 24 hours” using a Pain NRS 
ranging from  0 to 5 (8 -11 years old) and  0 to 10 (12-17 years old) .  For children less than 8 years 
old, caregivers will complete an observer -reported outcome ranging from 0 to 10.  Patients  or 
caregivers  will be provide d with an electronic diary tool during screening to record information 
daily pertaining to the patient’s worst abdominal pain  experience.  
Urgency  Numeric Rating Scale :   
 
 
  
 
9.1.8.  Histopathology Scoring Instrument  
The histopathology instruments that will be used for the evaluation of microscopic  inflammation 
and histopathologic disease activity will be specified in the histopathology charter . 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 82 
LY3074828  9.1.9.  Exploratory Assessments  
Exploratory endpoints are found in Table  AMBU .2.  Additional details are provided below.  
9.1.9.1.  Inflammatory Biomarker s 
Fecal calprotectin:   Fecal calprotectin is a complex consisting of the calcium -binding proteins 
S100A8 and S100A9.  It is expressed by activated  neutrophils (and to a lesser extent by 
macrophages and monocytes) , and fecal levels correlate with the number of neutrophils in the 
gut (Sands 2015 ).  It is used as a biomarker of intestinal inflammation in clinical practice.  Fecal 
calprotectin will be o btained at time points described in the Schedule of Activities (Section 2).   
C-reactive protein (CRP) :  C-reactive protein  is an acute phase protein expressed by 
hepatocytes in response to inflammatory cytokines, particularly IL -6, TNF , and IL -1β 
(Sands  2015 ).  C-reactive protein will be obtained at the time points described in the Schedule of 
Activities (Section 2).   
9.1.9.2.  Patient -Reported Outcome /Observer -Reported Outcome  Instruments  for 
Exploratory Assessments  
Observer -reported outcomes will be used in place of patient -reported outcomes for children less 
than  of age.   
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 83 
LY3074828  9.1.9.3.  Extraintestinal Manifestations  
Review of extraintestinal manifestations (EIMs) will be performed at the time points  described in 
the Schedule of Activities ( Section  2).  Extraintestinal manifestations  that occur prior to baseline 
or existing EIMs that change in severity  or resolve during the study  will be documented on the 
appropriate eCRF .  Extraintestina l manifestations  include, but are not limited to:   
 
 
9.1.9.4.  Physician -Reported Instrument  
9.1.10.  Appropriateness of Assessments  
All of the clinical and safety assessments in this study are standard, widely used, and generally 
recognized as rel iable, accurate, and relevant.  The disease activity measurements are used in 
clinical practice and UC clinical trials , and the health outcomes measures will allow assessment 
of symptoms and quality of life that are important to patients and their caregivers .  
Immunogenicity monitoring will provide information for future development of mirik izumab . 
9.2. Adverse Events  
Investigators are responsible for monitoring the safety of  patients  who have entered this study 
and for alerting Lilly or its designee to any event that seems unusual, even if this event may be 
considered an unanticipated benefit to the patient . 
The investigator is responsible for the appropriate medical care of patients  during the study.  
Investigators must document their review of each laboratory safety report.  
The investigator remains responsible for following, through an appropriat e health care option, 
AEs that are serious or otherwise medically important, considered related to the investigational 
product or the study, or that caused the patient  to discontinue the investigational product before 
completing the study.  The patient  should be followed until the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency of follow -up 
evaluations of the AE is left to the discretion of the investigator.   The investigator will record all 
relevant AE/SAE information in the eCRF . 
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.  
After the ICF is signed, study site personnel will record via eCRF the occurrence and nat ure of 
each patient ’s preexisting conditions, including clinically significant signs and symptoms of the 
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 84 
LY3074828  disease under treatment in the study.   In addition, site personnel will record any change in the 
condition(s) and any new conditions as AEs .  Investigators should record their assessment of the 
potential relatedness of each AE to protocol procedure  or investigational product, via eCRF.   
The investigator will interpret and document whether or not an AE has a reasonable possibility 
of being relate d to study drug, study device, or a study procedure, taking into account the 
disease, concomi tant treatment , or pathologies.  
A “reasonable possibility” means that there is a cause and effect relationship between the 
investigational product, study device and/or study procedure and the AE.   The investigator 
answers yes/no when making this assessment.  
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the stu dy. 
If a patient ’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via eCRF , clarifying if possible, the circumstances 
leading to any dos age modifications, or discontinuations of treatment.   
Care will be taken not to introduce bias when detecting AEs or SAEs.  Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
Cardiovascular  and venous thromboembolic  AEs and other events leading to death are collected 
as described in Section  9.2.1  and its subsections ; also see Section  9.2.2.4 . 
9.2.1.  Serious Adverse Events  
An SAE is any AE from this study that results in one of the following outcomes:  
 Death 
 Initial or prolonged inpatient ho spitalization  
 A life-threatening experience (that is, immediate risk of dying)  
 Persistent or significant disability/incapacity  
 Congenital anomaly/birth defect  
 Important medical events that may not be immediately life -threatening or result in 
death or hospitali zation but may jeopardi ze the patient or may require intervention 
to prevent one of the other outcomes listed in the definition above.   Examples of 
such medical events include allergic bronchospasm requiring intensive treatment 
in an emergency roo m or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of drug dependency or drug 
abuse.  
All AEs occurring after signing the ICF are recorded in the eCRF , assessed for serious criteria , 
and all ser ious cri teria that are met are recorded in the eCRF.   The required timeframe for  SAE 
reporting to the sponsor begins after the patient  has signed the ICF and has received 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 85 
LY3074828  investigational product.  However, if an SAE occurs after signing the ICF, but prior to receiving 
investigational product, the SAE should be reported to the sponsor as per SAE reporting 
requirements and timelines (see Section  9.2) if it is considered reasonably possibly related to 
study procedure.  
Study site personnel must alert Lilly or its designee of any SAE within 24 hours of investigator ’s 
awareness of the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately followed with official notification on study -specific SAE forms.  This 
24-hour notification requirement refers to the initial SAE information and  all follow -up SAE 
information.  Patients  with a  should have additional data collected using the 
hepatic e CRF . 
Pregnancy ( during maternal or paternal exposure to investigational product) does not meet the 
definition of an AE.  However, to fulfill regula tory requirements , any pregnancy that begin s at 
any point after the start of study drug and until at least  after the participant’s last dose 
of study drug  should be reported following the SAE process to collect data on the outcome for 
both mother and fetus.    
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study ( that is, the patient  disposition case report form has 
been completed).  However, if the investigator learns of any  SAE, including a death, at any time 
after a subject has been discharged from the study, and he/she considers the event reasonably 
possibly related to the study drug or study participation, the investigator must promptly notify 
Lilly.  
9.2.1.1.  Suspected Unexpected Serious Adverse Reactions  
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not  listed 
in the IB and that the investigator identifies as related to investigational product or procedure.  
United States 21 CFR 312.32 and Eur opean Union Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory requirements in participating countries 
require the reporting of SUSA Rs.  Lilly has procedures that will be followed for the 
identification , record ing, and expedited reporting of SUSARs that are consistent with global 
regulations and the associated detailed guidances.  
9.2.1.2.  Regulatory Reporting Requirements for Serious Adverse Events  
Prompt notification by the investigator to the sponsor of an SAE as stated in Section 9.2.1  is 
essential so that legal obligations and ethical responsi bilities towards the safety of participants 
and the safety of a study intervention under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation.  The 
sponsor will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, Institutional Review Boards (IRB s)/Independent Ethics Committees 
(IEC s), and  investigators.  
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 86 
LY3074828  Investigator safety reports must be prepared for SUSARs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.  
An investigator who receives an investigator safety report describing an SAE or other specific 
safety information (for example, summary or listing of SAEs) from the sponsor will review and 
then file it along with the IB and will notify the IRB/IEC, if appropriate according to local 
requirements.  
9.2.2.  Adverse Events of Special Inter est 
Adverse eve nts of special interest (AESIs), which are not necessarily ADRs  but are  of special 
interest based on standard drug registration topics, safety findings from previous studies in the 
development program, potential risks associated with biologic imm unomodulators as noted in 
product labels and published literature, and comorbidities and risk factors prevalent in the 
studied populations.  The AESIs for this study are defined in the SAP, and may include but are 
not limited to : 
Additional samples and data will be collected for hypersensitivity events ( Section  2).  For some 
AESIs, sites should  provide additional information regarding the event, as instructed on the 
eCRF.   For all AESIs, including hypersensitivity events, the protocol and IB provide monitoring 
and management guidance to the investigator.  
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 87 
LY3074828  9.2.3.  Complaint Ha ndling  
Lilly collects product complaints on investigational products and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product improvements.  
Patients  will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational produ ct so that the situation can be assessed.  
9.3. Treatment of Overdose   
In case of suspected overdose, participants should be monitored for any signs or symptoms of 
adverse reactions or effects, and  hematology, chemistry, vital signs, and oxygen saturation 
should  be monitored ; supportive care should be provided as necessary.  The medical monitor and 
sponsor must be informed as soon as possible when an overdose has been identified, and all AEs 
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 88 
LY3074828  associated with the overdose will be recorded in the eCRF.   
 
9.4. Safety  
When multiple safety assessments are scheduled for the same visit, the preferred order of 
completion is as follows:   
9.4.1.  Vital Signs  
Measurements of vital signs (body temperature, blood pressure , and pulse  rate) will be  conducted 
at the study visits specified in  the Schedule of Activities (Section 2).   
Sitting blood press ure and pulse rate should be measured after the patient  has been sitting for at 
least 5 minutes.  
Any clinically significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient  receives the first dose of study drug should be reported to Lilly or its 
designee as an AE  via eCRF.  
9.4.2.  Electrocardiograms  
Electrocardiograms  ( ) should be collected according to the Schedule of Activities 
(Section 2).   
Electrocardiograms  should be completed prior to any blood draw.  Participants should be supine 
for approximately 5 to 10 minutes before ECG collection and should remain supine and awake 
during ECG collection.  
Evaluation of ECGs should be performed by appropriately trained personnel with experience in 
reading pediatric ECGs.  Electrocardiograms  will be read locally  by a health care professional 
trained in the reading of pediatric ECGs . 
Any clinically significant findings from ECGs that result in a diagnosis and that occur after the 
patient  receives the first dose o f the investigational treatment s hould be reported to Lilly or its 
designee as an AE via eCRF.  
9.4.3.  Laboratory Tests  
Laboratory te sts detailed in Appendix 2  should be conducted according to the Schedule of 
Activities (Section 2).  
Retesting is allowed during the screening period (see Sectio n 6.4.1 ). 
Additional clinical laboratory tests, including local tests, may be performed at any time during 
the study as determined necessary by the investigator for immediate participant management or 
safety or as required by local regulations.   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 89 
LY3074828  Except where otherwise stated (for example, ), samples for laboratory 
tests should be collected prior to dosing.  
Unless noted as locally performed (for example, urine pregnancy tests), clinical laboratory tests 
will be sent to a central laboratory for testing.  
Lilly  or its designee  will provide the investigator with the results of laboratory tests analyzed by 
a central  vendor, where appropriate.  
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient  receives the first dose of investig ational product should be reported to Lilly or its 
designee as an AE  via eCRF . 
9.4.3.1.  Pregnancy Testing  
Female  subjects of childbearing potential will undergo a urine pregnancy test at the clinic  
 during s cheduled visits through Week 52 .  
Childbearing potential is defined as females meeting one or more of the following criteria:  
Serum pregnancy test will be done at screening only and results will be confirmed by the central 
laboratory.  Patients determined to be pregnant will be discontinued from the study.  
Urine pregnancy testing will be performed locally during designated scheduled visits through 
Week 52.  The urine pregnancy test must be “negative”  within 24 hours prior to administration 
of study drug at every study visit . 
Urine pregnancy testing may be performed at additional time points during the treatment period 
and/or follow -up period, at the discretion of the investigator or if this is required by local 
regulations.  
If a urine pregnancy test is not available, a serum pregnancy test is an acceptable alternative.  
9.4.3.2.  Hormone Testing  
 will be collected to assess the onset of puberty in patients 
aged  and older who have not attained full maturation by Visit 1  and at other visits 
specified in the Schedule of Activities (Section  2). 
9.4.4.  Immunogenicity Assessments  
At the visits and times specified in the Schedule of Activities  (Section 2), venous blood samples 
will be collected to d etermine antibody production against mirikizumab.   
 Pre-dose samples will be obtained per the S chedule of Activities . 
 The actual date and time (24 -hour clock time) of each sample collection will be recorded.  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 90 
LY3074828  To aid interpretation of these results, a pre -dose blood sample for PK analysis will be collected at 
the same time points.  
In the event of a systemic allergic/hypersensitivity reaction (Sectio n 9.2.2.2 ), additional blood 
samples will be obtained as specified in the S chedule of Activities  (Section  2). 
Sample collection, handling, and use  
Instructions for the collection and handling of blood samples will be provided by the sponsor . 
Immunogenicity will be assessed by a validated assay designed to detect ADAs in the presence 
of mirikizumab at a laboratory approved by the sponsor.  Antibodies will be further evaluated for 
their ability to neutralize the activity of mirikizumab.  
Sample retention  
Samples will be retained for a maximum of  after the last patient visit, or for a shorter 
period if local regulations and ERBs allow,  at a facility selected by the sponsor.  The duration 
allows the sponsor to respond to future regulatory requests related to mirikizumab .  Any samples 
remainin g after  will be destroyed.   
9.4.5.  Other Tests  
9.4.5.1.  Physical Examination  
Physical examination s are mandated and will be performed as specified in the Schedule of 
Activities (Section  2).  Physical examination s can also be performed at the discretion of the 
investigator at any additional timepoints, for example, to assist in the evaluation of a new 
symptom during the study.    
At screening, 1 complete physical examination (excluding pelvic, rectal, and breast 
examinations) will be performed and will include an assessment of peripheral lymph nodes.  
After screening, p hysical examination s should include a symptom -directed evaluat ion, as well as 
examination of  eyes,  heart, lungs, abdomen, and skin.  For all participants, a thorough exam to 
evaluate for TB  will be performed (Section  9.4.5.2 ). 
Any clinica lly significant findings from physical examination s that result in a diagnosis and that 
occur after the patient receives the first dose of investigational product should be reported to 
Lilly or its designee as an AE  via eCRF .  
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 91 
LY3074828  9.4.5.2.  Tuberculosis Testing  
Initial Screening  
All patients will be screened for active TB and LTBI.   Screening for LTBI (Visit 0) will include 
the following:  
 Thorough medical and social history to determine ri sk factors for TB infection over 
lifetime, symptoms or signs of active TB, and physical examination , including body 
temperature measurement and assessment of peripheral lymph nodes, as described in 
Section 9.4.5.1 . 
 Two tests to assess immune response to mycobacterial antigens  (unless patient has a 
history of a positive IGRA ): 
o IGRA (for example , QuantiFERON -TB Gold or T -SPOT.TB), and 
o Tuberculin skin test (TST, also called a purified protein derivative [ PPD] or 
Mantoux te st). 
 CXR, as de scribed in Section  9.4.5.3 . 
This testing paradigm follows the recommendation from NASPGHAN for pediatric patients with 
IBD starting on anti -TNF therapy (Ardura et al. 2016).  
Tests for Immune Response to Mycobacterial An tigens  
Patients with documentation of a “negative” IGRA or TST within  before initial  
screening may not need to repeat TB testing at screening, based on judgment of the investigator.   
Source documentation must include the original laboratory report  (for IGRA) or a record of the  
size in millimeters of the induration response (for TST).  A TST recorded as “negative” without  
documenting the size of induration in millimeters will not be acceptable and will require a retest.   
Interpretat ion of Screening Tests for LTBI  
The QuantiFERON -TB Gold assay will be reported as negative, indeterminate , or positive.  The 
T-SPOT assay will be reported as negative, borderline , or positive.  
The TST should be read 48 to 72 hours after test application.   Skin induration  in diameter 
is interpreted as positive in patient s without a BCG vaccination history.  In patients with a prior  
BCG vaccination history , a positive result  shall  be defined using  local criteria 
recommendation/guideline s.  Any questions should be referred to the medical monitor.  
Patients with a diagnosis of LTBI based on a positive IGRA test result or a positive TST 
response, and no evidence of active TB on medical history, physical examination, and CXR, may 
be evaluated as described in  Retesting and Confirmatory testing or rescreened once , as indicated 
in Section 6.4.  
Patients  may be enrolled in the study if they are treated for LTBI and meet the following 
requirements:  
 No history of risk of re -exposure since their treatments were completed  
 Have received a t least  of appropriate ongoing prophylactic therapy for LTBI, 
based on national or international guidelines, for example, United States Centers for 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 92 
LY3074828  Disease Control and Prevention (CDC 2016); or the World Health Organization (WHO 
2018), with documen tation of having completed the appropriate TB prophylaxis regimen,  
 No evidence of reactivation of LTBI,  and 
 Have no evidence of  hepatotoxicity (ALT and AST levels must remain ≤2 xAA ULN) 
upon retesting of serum ALT and AST levels before treatment assignment ). 
Such patients must meet all other inclusion and exclusion criteria for participation, and also must 
continue and complete appropriate LTBI therapy during the course of the study to remain 
eligible to participate .   
Retesting and Confirmatory Testing  
One retest is allowed for patients with an “indeterminate” QuantiFERON -TB Gold assay or 
“borderline” T -SPOT assay.  Patients with 2 indeterminate QuantiFERON -TB Gold assay s or 2 
borderline T -SPOT assay s will be required to have a CXR  (see Section 9.4.5. 3).  If both the CXR 
and TST are negative and there are no other risk factors for TB exposure present, the patient is 
eligible to be enrolled in the study.  
Confirmatory testing with an IGRA is allowed for selected patients who have a positive TST, 
positive Quant iFERON -TB Gold assay  or positive T -SPOT assay  who meet all of the following 
criteria, and are assessed by the investigator as likely having a false -positive test result:  
 No risk factors for LTBI  
 No risk factors for increased likelihood of progressing from LTBI to active TB, and  
 Have never resided in a high -burden country, as detailed in Appendix 8 .   
If the confirmatory test is positive, the patient will be excluded from the study unless they 
complete at least  of appropriate therapy for LTBI  based on national or international 
guidelines (as defined above) , and have no evidence of hepato toxicity  
 upon retesting of serum  of 
LTBI treatment .  Such patients must continue and complete appropriate full course of LTBI  
therapy  during the course of the study to remain  eligible to participate  in the study .  If the 
confirmatory test is negative,  these results will be discussed with the medical monitor in order to 
determine eligibility for the study.  
Patients  with a negative TST or IGRA can be re -tested with an IGRA wher e, in the judgement of 
the investigator, the initial test result may be a false negative, for example, due to a technical 
difficulty in administering the TST or due to concomitant immunosuppressant therapy.  
Monitoring for TB During the S tudy  
For all patien ts, monitoring for TB is to be continuous throughout the study.  At a minimum, 
each participant is to have the following documented at least every   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 93 
LY3074828  If the patien t has a risk factor  (Appendix 8 ), the investigator should collect , as de scribed 
in Section  9.4.5.3  
Diagnosis of LT BI During Study  
Patients diagnosed with LTBI during the study  
  If treatment for LTBI is considered to be appropriate, the patient must 
complete  of appropriate  therapy for LTBI , based on national or international 
guidelines (as defined a bove), and have no evidence of  hepatotoxicity  
upon retesting of serum ALT and AST levels after at least  of 
LTBI treatment .  Such patients may then resume study drug and must continue with and 
complete a ful l course of treatment for LTBI  in order to continue on study drug.   Non-
compliance with LTBI treatment during the study is a reason for permanent discontinuation from 
study drug  (Section 8.1.1 ).  
Household Contact  
Throughout the study, patients  who have had household contact with a person with active TB 
must be evaluated for TB infection.  
Prior Treatment for LTBI  
Patients who have a documented history of completing an appropriate TB prophylaxis regimen 
with no history of risk of re-exposure since their treatments were completed and no evidence of 
active TB are eligible to participate in the study.  These pa tients s hould not undergo TST or 
IGRA testing unless advised to do so based on local guidelines.   
Active TB  
Patient s with a past history of active TB, without documented treatment by WHO and/or CDC 
criteria are excluded from the study (Section  6.2). 
Patients diagnosed with active TB at screening will be excluded (Section 6.2) and shou ld be 
referred by the investigator for appropriate TB treatment and follow -up. 
If a pa tient is diagnosed with active TB during the study, the study drug will be permanently 
discontinued (Section 8.1.1 ), and the patient will undergo an ETV and then enter the post -
treatment follow -up period.  The patien t should also be referred by the investigator for 
appropriate TB treatment and follow -up. 
9.4.5.3.  Chest Radiography  
A posterior -anterior  chest x -ray (CXR), interpreted and reported by a radiologist or 
pulmonologist,  may be obtained at screening , as specified in the Schedule of Activities  
(Section  2) if both the TST and QuantiFERON -TB Gold assay  or T-Spot assay  are indeterminate 
or borderline.  A CXR  may be taken at any time in the study at the discretion of the investigator 
when clinically indicated, for example, as  part of an evaluation for active TB and LTBI .  A 
lateral CXR can also be obtained, if  in the opinion of the investigator , a lateral view is indicated.  
The CXR will be performed and interpreted locally.  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 94 
LY3074828  A CT scan can be performed as an alterna tive to the CXR based on regional standard of practice.  
The CT scan will be performed and interpreted locally.  
If the CXR or CT is performed for TB evaluation, it should be interpreted and reported by a 
radiologist or physician who specializes in the trea tment of TB. 
Certain findings from CXR may be consistent with a condition that excludes a participant from 
the study; see Section 6.2.   
9.4.5.4.  Hepatitis B Testing  
HBV Screening and Interpretation  
Exclusion Based on HBV Serology and HBV DNA Testing  
Patients Potentially Allowed into the Study, Based on HBV Serology and HBV DNA 
Testing  
Management of Patients with the Following HBV Serology at Baseline:  HBsAg -, 
anti-HBc+, HBV DNA Not Detected  
Management of Patient s with a Newly Positive anti -HBc Test During the Study  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 95 
LY3074828  Management of Patients with Detectable HBV DNA During the Study  
9.4.5.5.  Hepatitis C Testing  
Patients w ith current h epatitis C infection  are excluded from the study.  
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 96 
LY3074828  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 97 
LY3074828  9.4.5.7.  Stool Testing  
Stool Culture  
A stool sample for culture will be obtained at screening.   
Patients must have a “negative” stool culture from which no enteric pathogens are isolated  in 
order to be enrolled .   
Retesting is allowed within the same screening period if there is a technical difficulty in 
performing or reporting the stool culture assa y, as stated in Section 6.4.1 .  
Patients who have a “positive ” stool culture  result  can be re -screened once, as sta ted in 
Section  6.4, provided that the following conditions have been met:  
 The patient  has been adequately treated, and  
o if antibiotics were prescribed, patient  has been off antibiotics for , or  
o if antibiotics were not prescribed,  or more has elapsed since resolution of 
acute symptoms and signs associated with the underlying intestinal infection.  
The stool culture should be retested prior to rescreening .  
Additional local stool culture/testing is allowed at the investigator’s discretion.  
Participants with a positive stool culture result are excluded from the study (see Section  6.2). 
C. difficile  
A stool sample for testing C. difficile  will be obtained at screening.   
This assay may be tested locally (if available  for antigen , toxin , and PCR reflex  evaluation ) or 
centrally for the presence of C. difficile  antigen (GDH) and toxin (toxin A and toxin B), followed 
by a possible reflex  to PCR  confirmatory test for C. difficile gene expression in the stool sample.  
See flow chart below.   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 98 
LY3074828  Retesting is allowed within the screenin g period if there is a technical difficulty in performing or 
reporting the C. difficile result, as stated in Section  6.4.1 . 
Patient s who test positive at screening for C. difficile can be rescreened once, as stated in 
Section  6.4, provided that the following conditions have been met:  
 The patien t has been adequately treated, and  
 The patien t has been off antibiotics for .  
Patien ts who have been adequately treated for C. difficile with fecal microbial transplantation or 
IV immunoglobulin therapy can be rescreened once for the study,  after completing their 
therapy.   
A C. difficile stool toxin assay should be repeated prior to rescreening.   
Patients with a positive test for C. difficile  toxin are excluded from the study (Section 6.2). 
9.4.6.  Safety Monitoring  
Lilly will periodically review evolving aggregate safety data within the study by appropriate 
methods.  
9.4.6.1.  Hepatic Sa fety Monitoring  
If a study patient experiences elevated , or  
, liver testing (described in Appendix 4 ) should be repeated within 3 to 5 days , 
including  
 to confirm the abnormality and to determine if it is in creasing or decreasing.  If the 
abnormality persists or worsens, clinical and laboratory monitoring should be initiated by the 
investigator and in consultation with the study medical monitor.   Monitoring of  
 should continue until leve ls normalize or return to approximate baseline levels.  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 99 
LY3074828  If a study patient  experiences an  and  or 
international normalized ratio , the study medical monitor should be consulted as soon as 
possible for further guidance on  evaluation of the laboratory abnormalities.  
Hepatic Safety Data Collection  
Additional safety data should be collected via the hepatic eCRF if 1 or more of the following 
conditions occur:  
 Elevation of serum ALT to  on 2 or more consecutive blood t ests 
 Elevated serum TBL to  (except for cases of known Gilbert’s 
syndrome )  
 Elevation of serum ALP  to  on 2 or more consecutive blood tests  
 Patient  discontinued from treatment due to a hepatic event or abnormality of 
liver tests  
 Hepatic event considered to be a SAE  
 Patient  with a history of HCV infection develops elevated ALT .  Patien t 
will be tested for HCV RNA.  
9.5. Pharmacokinetics  
At the visits and times specified in the Schedule of Activities  (Section 2), venous blood samples 
will be collected to determine the serum concentrations of mirikizumab .  Pre-dose samples can 
be collected at any time prior to dosing during the visi t, and post -dose samples should be 
collected within  after dosing.  
Collection, handling, and storage of samples  
Instructions for the collection and handling of blood samples will be provided by the sponsor .  
The actual date and time (24 -hour clock time) of each sampling will be recorded.   Samples will 
be analyzed at a laboratory approved by the sponsor and stored at a facility designated by the 
sponsor.   Serum  concentrations of mirikizumab  will be determined using a validated enzyme -
linked immunosor bent assay .   
Additional samples  
A maximum of 3 additional samples may be collected at additional time points during the study 
if warranted and agreed upon between both the investigator and sponsor.  In the case of systemic 
allergic/hypersensitivity reacti ons (Section 9.2.2.2 ), additional blood samples will be obtained, as 
described in the S chedule of Activities  (Section 2). 
  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 100 
LY3074828  Sample retention  
Bioanalytical samples collected to measure investigational product concentration will be retained 
for a maximum of  following last patient visit for the study.  
9.6. Phar macodyna mics  
See Section  9.8. 
9.7. Pharmacogenomics   
 
 
  
 
 
 
   
  
may be tested.  These are genetic markers that are related to 
the biology of inflammatory and autoimmune disease.  
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by the investigator site personnel.   
Sample retention  
Samples will be retained at a facili ty selected by Lilly or its designee  for a maximum of  
after the last  patient  visit for the study, or for a shorter period if local regulations and/or ERBs 
impose shorter time limits.  This retention period enables use of new technologies, response  to 
regulatory questions, and investigation of variable response that may not be observed until later 
in the development of  mirikizumab  or after  mirikizumab  becomes commercially available.  
Molecular technologies are expected to improve during the  and therefore , 
cannot be specifically named.  However, existing approaches include whole genome or exome 
sequencing, genome wide association studies, and candidate gene studies.  Regardless of the 
technology utilized , genotyping data generate d will be used only for the specific research scope 
described in this section.  
9.8. Biomarkers  
 
 
  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 101 
LY3074828  Sample use  
Biomarker research is performed to address questions of relevance to drug disposition, target 
engagement, PD, mechanism of action, variability of patient respo nse (including safety), and 
clinical outcome.  Sample collection is incorporated into clinical studies to enable examination of 
these questio ns through measurement of biomolecules , including DNA, RNA, proteins, lipids, 
and other cellular elements.  
Samples will be used for research on the drug target, disease process, variable response to 
mirikizumab , pathways associated with  UC, mechanism of action of mirikizumab , and/or 
research method , or in validating diagnostic tools or assays related to  UC.   
All samples will be coded with the patient  number.  These samples and any data generated can 
be linked back to the patient  only by the investigator site personnel .   
Sample retention  
Samples will be retained at a facility selected by Lilly or its designee  for a maximum of  
after the last patient  visit for the study, or for a shorter period if local regulations and ERBs 
impose shorter time limits.  This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed until later 
in the development of mirikizumab  or after mirikizumab  become s commercially available . 
9.9. Medical Resource Utilization and Health Economics  
Sites should provide information regarding healthcare visits, including hospi talizations and 
surgeries for UC , as instructed on the eCRF.  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 102 
LY3074828  10. Statistical Considerations  
10.1.  Sample Size Determination  
Lilly plans to enroll approximately 30  patients into Study AMB U, to achieve  at least 25 
evaluable patients  with respect to evaluating mirikizumab PK .  The enrollment target includes 
approximately  patie nts in the > 40 kg category and approximately  patients in the ≤40 kg 
category.   
This sample size is considered adequat e to evaluate the PK of mirikizumab treatment in pediatric 
patients.  
10.2.  Populations for Analyses  
For purposes of analysis, the populations are defined  in Table  AMB U.6. 
Table  AMB U.6. Population Definitions  
Population  Description  
Modified  Intent -to-Treat 
(mITT) Population  All enrolled  patients  that took at least 1 dose of treatment , even if the patient  
does not receive the correct treatment, or otherwise does not follow the 
protocol.   Patients will be analyzed according to the treatment to which they 
were assigned .  Unless otherwise noted, efficacy and health outcomes analyses 
will be conducted on  this population.  
Induction Safe ty All Induction ITT  patients  who received at least 1 dose of the study drug.  
Patients  will be analyzed according to the treatment to which they were 
assigned.   Safety analyses for the induction period will be conducted on  this 
population.  
Maintenance Safe ty All Maintenance ITT  patients  who have received at least 1  maintenance dose .  
Safety  analyses for the maintenance period will be conducted on  this 
population.  
PK evaluable  All patients who received at least 1 dose of investigational product and have 
sufficient blood sampling to allow for PK evaluation . 
Abbreviation s:  ITT = intent -to-treat;  PK = pharmacokinetic . 
 
Additional populations will be defined in the SAP.  
10.3.  Statistical Analyses  
10.3.1.  General Statistical Considerations  
Statistical analysis of this study will be the responsibility of Lilly o r its designee.  
Efficacy analyses for the induction period  and the maintenance period  will be conducted on the 
modified ITT population.  Safety analyses for the induction period  and the maintenance period  
will be conducted on the induction safety population and the maintenance safety population , 
respectively.   
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 103 
LY3074828  Summary statistics for continuous variables  will include mean, standard deviation, median, and 
minimum and maximum values; categorical variables will be presented as counts and 
percentages.   
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a  principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the clinical study report  (CSR) .  Additional exploratory analyses of the data wi ll be conducted 
as deemed appropriat e.  Full details of these analyses will be provided in the SAP.   
10.3.1.1.  Missing Data Imputation  
While every effort will be made to reduce missing data, the  missing data imputation method of 
NRI will be used when patients are permanently discontinued from study drug or otherwise have 
missing data.  
For analysis of categorical efficacy and health outcomes variables, missing data will be imputed 
using an NRI method.  Patients will be considered a no nresponder for the NRI analysis if they do 
not meet the categorical response criteria or have missing clinical response data at a time point of 
interest.   
Imputation details based on NRI will be provided in the SAP.  Additional missing data  
imputation met hodologies may be considered and will also be fully detailed in the SAP.  
10.3.2.  Treatment Group Comparability  
10.3.2.1.  Patient  Disposition  
The number of enrolled  patients will be summarized.  Frequency counts and percentages of all 
patients who are enrolled  and completing  the study or discontinue the study drug/study early will 
be presented.  Reasons for discontinuing the study drug/study will be summarized.  
10.3.2.2.  Patient  Characteristics  
Full d ate of birth  (unless prohibited by local law) , sex, weight, height, smoking habits, previous 
biologic therapy, corticosteroid use , and other demographic characteristics will be recorded.  Age 
and body mass index will be calculated.  Demographic and baseline characteristics will be 
summarized for each treatment group.   Certain characterist ics, such as weight, that are collected 
after baseline, will be reported as a listing .   
10.3.2.3.  Concomitant Therapy  
Concomitant therapy will be collected at each visit, and the reported term will be classified by 
the World Health Organization drug dictionary.  Pr evious concomitant therapy (reported before 
study enrollment ) and current concomitant therapy (reported after study enrollment ) will be 
presented separately in frequency tables by drug name for all enrolled  patients . 
10.3.2.4.  Treatment Compliance  
Patients who are n oncompliant will be listed by treatment.  A contingency table of numbers of 
noncompliant patients by treatment will be provided.  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 104 
LY3074828  10.3.3.  Efficacy Analyses  
10.3.3.1.  Primary Analyses  
The primary objective of this study is to evaluate the PK of mirikizumab treatment in pediat ric 
patients.  See Section 10.3.5  for a description of PK analyses.  
10.3.3.2.  Secondary Analyses  
The secondary  efficacy endpoint of clinical remission will be assessed using the MMS, a 9 -point 
instrument that includes the SF, RB , and ES subscores of the Mayo Score.  
The SF and RB sub scores of the Mayo Score will be calculated from daily electronic diary  data 
by ave raging the most recent  (possibly non -consecutive) prior to the Week 52 visit  or 
 prior to the Week 52 bowel prep aration /endo scopy .  If data from fewer than  are 
available from the  to Week 52 visit, the subscores will be cons idered as missing.   
The  of patient diary data must exclude data from days when bowel preparation or 
endoscopic exam (flexible proctosigmoidoscopy/colonoscopy) occur and exclude data from the 
day after the endoscopic exam.   
To calculate the SF subscore, the reference  SF will be subtracted from the  averaged SF.  
The subtracted SF value will  then be rounded to the nearest integer and then mapped to obtain 
Mayo SF subscore.    
To calculate the RB subscore, the  RB scores will be averaged and the RB subscore  will be 
rounded to the nearest integer .  Rates of clinical remission at Week 12, as defined in 
Section  9.1.1 , will be analyzed.  Pat ients who do not achieve clinical remission or who do not 
reach the Week 12 assessment will be considered to be nonremitters.  
Descriptive summaries by treatment, by visit , and by weight group  for this endpoint , as well as 
for the rest of the secondary eff icacy endpoints described in Table  AMBU .2 will be performed 
using NRI methodology.  
Additional analyses of the  secondary  endpoint may be considered and details will be provided in 
the SAP.  
10.3.3.3.  Tertiary/Exploratory Analyses  
The exploratory endpoints of the trial are presented in Table  AMBU .2.  Details of the analys es of 
exploratory endpoints , as well as additional explora tory endpoints  will be  described  in the SAP.  
10.3.4.  Safety Analyses  
Safety data will be summarized by dose.  Safety and tolerability including but not limited to AEs, 
infections, injection site reactions, clinical chemistry, hematology, immunogenicity, tolerability 
and acceptability of SC injection volumes of , and questionnaires to assess the existence 
and severity of depression  will be assessed .   
For AEs, the number  of treatment -emergent adverse event s (TEAEs ), as well as the number and 
percent age of patients who reported  at least 1 TEAE  will be summarized using Medical 
Dictionary for Regulatory Activities  (MedDRA ) for each system organ class and preferred term .  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 105 
LY3074828  Serious adverse events (including deaths), treatment -emergent AESIs, and AEs that lead to  
treatment  discontinuation will also be summarized using MedDRA  for each system organ class 
and preferred term.  
For lab oratory analytes and vital  signs,  treatment -emergent abnormal shifts to low/high will be 
presented.  
Summary tables or listings for   will be  produced as needed.  
Immuni zation history will be recorded at baseline, and any unexpected outcomes or effects 
related to standard of care vaccination during the study will be summarized . 
Further analyses may be performed as dee med appropriate and will be detailed in the SAP.  
10.3.5.  Pharmacokinetic/Pharmacodynamic Analyses  
Analyses of the PK of mirikizumab and relationships between exposure and the efficacy 
endpoints will be conducted.  For both the PK and exposure -response analyses, in trinsic and 
extrinsic factors will be evaluated to determine their impact.  Comparisons of adult and pediatric 
PK and exposure -response will be performed and may be combined if appropriate.  
The PK of mirikizumab  will be characterized 
 
 
 
   
Analyses of exposure -response relationships may be conducted using both exploratory graphical 
approaches and model based approaches.  Exploratory graphical analysis approaches may consist 
of graphs showing the change in
versus exposure of mirikizumab .  Model based analyses may utilize population exposure -
response models, where maximum effect (E max) or other model structures may be used to relate 
mirikizumab exposure to the probability of achieving clinical response, clinical remission, 
endoscopic healing , or change in the MMS score .  These models may be used to evaluate patien t 
factors that may impact the exposure -response relati onship s.  Similar graphical and model based 
analyses relating mirikizumab  exposure to  
 may also be conducted.   
Additional analyses may be conducted if they are deemed appropriate.  Dat a from this study may 
be combined with other study data, if appropriate.  Comparison of data in this study with data 
from adult studies will be addressed in a separate analysis plan.  Further details on PK and 
exposure -response  analyses will be provided in the PK/PD analysis plan.  
10.3.6.  Evaluation of Immunogenicity  
The frequency  and percentage  of patients with preexisting (baseline) ADA, ADA at any time 
post baseline, and with treatment -emergent anti -drug antibody (TE ADA ) to mirikizu mab will be 
tabulated .  If no ADAs are detected at baseline, TEADA s are defined as those with a  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 106 
LY3074828   greater than the minimum required dilution (MRD) of the assay.  For samples with 
ADA detected at baseline , TEADA s are defined as those  with a  increase in 
titer compared to baseline.  For patients who have  TEADA , the distribution of maximum titers 
will be described.  The frequency of neutralizing antibodies will also be tabulated.  
The relationship between the presence  of antibodies and the PK parameters and PD response 
including safety and efficacy to mirikizumab  will be assessed.  
10.3.7.  Other Analyses  
10.3.7.1.  Subgroup Analyses  
Subgroup analyses may be conducted for select secondary endpoints.  Subgroups to be evaluated 
may include sex, age , weight ( ≥40 kg versus  <40 kg), race, 
geographic region, baseline disease severity, duration of disease, previous use of biologic 
therapy, and no previous use of biologic therapy .  Details of the subgroups  and associated 
analyses (including any additional subgroups ) will be defined in the SAP . 
10.3.8.  Data Snapshot  and Interim Analyses  
The planned data snapshot and interim analyses are described as follows.  
10.3.8.1.  Data Snapshots  
There will be 2 data snapshots taken of PK and safety data : 
 The first snapshot will be taken when at least  patients reach Week 4.  This will provide 
an early assessment of PK and safety data .  This analysis is planned to enable dose 
confirmation for the Phase 3 study for patients >40 kg.  
 The second snapshot will be taken when approximately  patients in the ≤ 40 kg grou p 
(5 mg/kg IV Q4W) reach Week 4 .  This analysis is planned to enable the enrollment of 
the 10 mg/kg treatment group . 
10.3.8.2.  Interim Analyses  
 An interim analysis is planned when appr oximately  patients in the ≤40 kg group reach 
Week 12.  This analysis will allow confirmation of dose for patients ≤40  kg to begin the 
Phase 3 study.  
No multiplicity adjustment will be made due to multiple comparisons or due to interim analyses.  
Addition al data snapshots and/or interim analyses may be performed as deemed necessary, based 
on emerging data from the study.  
Study sites will receive information about interim results ONLY if it is required for the safety of 
their patients.  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 107 
LY3074828  11. References  
Ardura MI , Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W.  NASPGHAN clinical report: 
surveillance, diagnosis, and prevention of i nfectious diseases in pediatric patients with 
inflammatory b owel disease receiving tumor n ecrosis factor -α inhibitors . J Pedi atr 
Gastroenterol Nutr . 2016 ;63(1):130 -155. 
Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico -Beyer LA, Gupta M, Tang M, Allison DE, Lu 
D, Zhang Y, Joshi A, Dresser MJ. A guide to rational dosing of monoclonal antibodies. Clin 
Pharmacokinet.  2012;51 (2):119-135. 
Benchimol EI, Guttmann A, Griffiths AM, Rabeneck L, Mack DR, Brill H, Howard J, Guan J, 
To T. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: 
evidence from health administrative data. Gut. 2009;58 (11):1490 -1497.  
Betteridge J D, Armbruster SP, Maydonovitch C, Veerappan GR. Inflammatory bowel disease 
prevalence by age, gender, race, and geographic location in the U.S. military health care 
population. Inflamm Bowel Dis . 2013;19(7):1421 -1427.  
Buse E. Development of the immune syst em in the cynomolgus monkey: the appropriate model 
in human targeted toxicology? J Immunotoxicol.  2005;2(4):211 -216. 
Button LA, Roberts SE, Goldacre MJ, Akbari A, Rodgers SE, Williams JG. Hospitalized 
prevalence and 5 -year mortality for IBD: Record linkage  study. World J Gastroenterol. 
2010;16(4):431 -438. 
[CDC] Centers for Disease Control an d Prevention. Treatment regimen s for latent TB infection 
(LTBI). CDC webpage. Available at: https://www.cdc.gov/tb/topic/treatment/ltbi.htm. April 
2016. Accessed April 16, 2019.  
[CUIMC] Columbia University Irving Medical Center. Columbia -Suicide Severity Rating Scale 
(C-SSRS). Available at: https://cssrs.columbia.edu/. Published 2016. Accessed December  14, 
2020. 
D’Haens G, Sanborn WJ, Ferrante M, Bhandari BR, Berliba E,  Hibi T, Tuttle J, Canavan JB, 
Friedrich S, Durante M, Arora V, Feagan B . OP38 maintenance treatment with mirikizumab, a 
p19-directed IL -23 antibody: 52 -week results in patients with moderate -to-severely active 
ulcerative coliti s. J Crohns Colitis.  2019; 13:S026 -S027.  
Di Domenicantonio R, Cappai G, Arca M, Agabiti N, Kohn A, Vernia P, Biancone L, Armuzzi 
A, Papi C, Davoli M.  Occurrence of inflammatory bowel disease in central Italy: A study 
based on health information systems. Dig Liver Dis. 2014;46 (9):777-782. 
Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin 
Pharmacokinet.  2010;49 (10):633–659.  
Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A 
population -based study. N Engl J Med . 1990;323(18):1228 -1233.  
[EMA] European Medicines Agency. Qualification opinion Paediatric Ulcerative Colitis Activity 
Index (PUCAI). CHMP/SAWP/801872/2015. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideli
ne/2016/01/WC500200026.pdf . January 2016a. Accessed April 10, 2019 . 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 108 
LY3074828  [EMA]  European Medicines Agency. Guideline on the development of new medicinal products 
for the treatment of Ulcerative Colitis.  CHMP/EWP/18463/2006 Rev. 1 . Available at: 
http://www.ema.eu ropa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC50
0211431.pdf . 2 July 2016b. Accessed  April 10, 2019 . 
[FDA] Food and Drug Administration . Ulcerative Colitis: Clinical Trial Endpoints, Draft 
Guidance for Indu stry. Available at: 
https://ww w.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/u
cm515143.pdf . August 2016.  Accessed April 10, 2019 . 
Horsburgh CR, Rubin EJ. Latent tuberculosis infection in the United States. N Engl J Med. 
2011;364 (15):1441 -1448. 
Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A, Otley A, Evans J, 
Pfefferkorn M, Rosh J, Rothbaum R, Kugathasan S, Mezoff A, Wyllie R, Tolia V, delRosario 
JF, Moyer MS, Oliva -Hemker M, Leleiko N; Pediatric Inflammatory Bowel Disease 
Collab orative Research Group. The natural history of corticosteroid therapy for ulcerative 
colitis in children. Clin Gastroenterol Hepatol . 2006;4(9):1118 -1123.  
Hyams JS, Lerer T, Mack D, Bousvaros A, Griffiths A, Rosh J, Otley A, Evans J, Stephens M, 
Kay M, Kel jo D, Pfefferkorn M, Saeed S, Crandall W, Michail S, Kappelman MD, Grossman 
A, Samson C, Sudel B, Oliva -Hemker M, Leleiko N, Markowitz J; Pediatric Inflammatory 
Bowel Disease Collaborative Research Group Registry. Outcome following thiopurine use in 
childr en with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol . 
2011;106(5):981 -987. 
Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, Kugathasan S, Cohen S, 
Markowitz J, Escher JC, Veereman -Wauters G, Crandall W, Balda ssano R, Griffiths A; T72 
Study Group. Induction and maintenance therapy with infliximab for children with moderate 
to severe ulcerative colitis. Clin Gastro enterol  Hepatol . 2012;10(4):391 -399. 
Illumina. Infinium® ImmunoArray -24 v2.0 BeadChip product infor mation sheet. 2015. 
Webpage. Available at: https://www.illumina.com/content/dam/illumina -
marketing/documents/products/product_information_sheets/infinium -human -immunoarray -24-
product -info-sheet -370-2015 -002.pdf. Accessed April 10, 2019 .  
Jakobsen C, Bartek  J Jr., Wewer V, Vind I, Munkholm P, Groen R, Paerregaard A. Differences 
in phenotype and disease course in adult and paediatric inflammatory bowel disease –a 
population -based study. Aliment Pharmacol Ther . 2011a;34(10):1217 -1224.  
Jakobsen C, Munkholm P, Pa erregaard A, Wewer V. Steroid dependency and pediatric 
inflammatory bowel disease in the era of immunomodulators –a population -based study. 
Inflamm Bowel Dis . 2011b;17(8):1731 -1740.  
Jostins  L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schu mm LP, 
Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, 
Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, 
Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L,  Balschun T, Bampton PA, 
Bitton  A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D ’Amato M, De Jong D, 
Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferg uson LR, Franchimont D, 
Fransen  K, Gearry R, Georges M, Gieger C, Glas J, Haritu nians T, Hart A, Hawkey C, 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 109 
LY3074828  Hedl  M, Hu X, Karlsen  TH, Kupcinskas L, Kugathasan S,  Latiano A, Laukens D, 
Lawrance  IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, 
Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, 
Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sve ntoraityte J, Targan SR, 
Taylor  KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wils on DC, 
Winkelmann  J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD 
Genetics  Consortium (IIBDGC), Silverberg MS, Annese V, Hakona rson H, Brant SR, 
Radford -Smith  G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, 
Vermeire S, Barrett JC, Cho JH. Host -microbe interactions have shaped the genetic 
architecture of inflammatory bowel disease.  Nature . 2012; 491(7422) :119-124. 
Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s 
disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci.  
2013;58 (2):519-525. 
Kova cs M. Children’s depression inventory (CDI 2) (2nd edition). Journal of Psycho educational 
Assessment . 2012 ;30(3): 304-308. 
Lewinsohn DM, Leonard  MK, LoBue  PA, Cohn  DL, Daley  CL, Desmond  E, Keane  J, 
Lewinsohn  DA, Loeffler  AM, Mazurek GH, O’Brien  RJ, Pai M, Richeldi  L, Salfinger  M, 
Shinnick  TM, Sterling  TR, Warshauer  DM, Woods GL. Official American Thoracic 
Society/Infectious Diseases  Society of America/Centers for Disease Control and  Prevention 
Clinical Practice Guidelines: diagnosis of  tuberculosis in adults and children. Clin Infect Dis.  
2017;64(2):111 -115. 
Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children 
and young adults with inflammatory bowel disease receiving infliximab. J Pediatr 
Gastroenterol Nutr . 2004;38(5):502 -508. 
Reich  K, Armstrong AW, Foley P, Song M, Wasfi  Y, Randazzo B, Li S, Shen YK, Gordon KB.  
Efficacy and safety of  guselkumab , an anti -interleukin -23 monoclonal antibody, compared 
with adalimumab for the treatment of patients with moderate to severe  psoriasis  with 
randomized withdrawal and retreatment: Re sults from the phase III, double -blind, placebo - 
and active comparator -controlled VOYAGE 2 trial.  J Am Acad Dermatol . 2017 ;76(3):418 -431. 
Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. 
JAMA Pediatr.  2015;169(11):1053 -1060.  
Sandborn WJ, Ferrante M, Bhandari BR, D’Haens GR, Berliba E, Feag an BG, Laskowski J, 
Friedrich S, Durante M, Tuttle J. Efficacy and safety of anti -interleukin -23 therapy with 
mirikizumab (LY3074828) in patients with moderate -to-severe ulcerati ve colitis in a phase 2 
study. Gastroenterology.  2018; 154(6):S1360 -S1361 . 
Sands  BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology . 
2015;149 (5):1275 -1285.e2 . 
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5 -amino salicylic acid therapy for mildly 
to moderately active ulcerative colitis. A randomized study. N Engl J Med.  
1987;317(26):1625 -1629.  
Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, 
Mamula P, Beaton DE, Steinhart AH, Griffiths AM.  Development, v alidation, and evaluation 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 110 
LY3074828  of a pediatric ulcerative colitis activity index: a prospective multicenter study. 
Gastroenterology.  2007; 133(2):423 –432. 
US Census Bureau population division website. Annual estimates of the resident p opulation for 
selected age groups by sex for the United States, states, counties and Puerto Rico 
commonwealth and municipios: April 1, 2010 to July 1, 2015. Available at: 
https://factfinder.census.gov/faces/tableservices/j sf/pages/productview.xhtml?src=bk mk. 
Accessed January 13, 2017.   
Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, Ouahed J, Wilson DC, 
Travis SP, Turner D, Klein C, Snapper SB, Muise AM ; COLORS in IBD Study Group and 
NEOPICS . The diagnostic approach to monogenic very ea rly onset inflammatory bowel 
disease. Gastroenterol ogy. 2014;147 (5):990-1007.  
[WHO] World Health Organization. Use of high burden country lists for TB by WHO in the 
post-2015 era. Available at: 
http://www.who.int/tb/publications/global_report/high_tb_burde ncountrylists2016 -2020.pdf . 
Accessed April 10, 2019 . 
[WHO] World Health Organization. Latent tuberculosis infection: updated and consolidated 
guidelines for programmatic management. WHO webpage. Available at: 
https://apps.who.int/iris/bitstream/handle/1066 5/260233/9789241550239 -
eng.pdf;jsessionid=E70CB8EF5698843C11B55E8D24622809?sequence=1. 2018.  Accessed 
April 16,  2019.  
Winthrop  KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, Bartalesi F, 
Lipman M, Mariette X, Lortholary O, Weinblatt ME, Saag M, Smolen J . Opportunistic 
infections and biologic therapies in immune -mediated inflammatory diseases: consensus 
recommenda tions for infection reporting during clinical trials and postmarketing surveillance. 
Ann Rheum Dis . 2015;74 (12): 2107 -2116 . 
Zeisler B, Lerer T, Markowitz J, Mack D, Griffiths A, Bousvaros A, Keljo D, Rosh J, Evans J, 
Kappelman M, Otley A, Kay M, Grossman A,  Saeed S, Carvalho R, Oliva -Hemker M, 
Faubion W, Sudel B, Pfefferkorn M, Ashai -Khan F, Leleiko N, Hyams J; Pediatric 
Inflammatory Bowel Disease Collaborative Research G roup. Outcome following 
aminosalicylate therapy in children newly diagnosed as having ul cerative colitis. J Pediatr 
Gastroenterol Nutr . 2013;56(1):12 -18. 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 111 
LY3074828  12. Appendices  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 112 
LY3074828  Appendix 1.  Abbreviations and Definitions  
 
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 113 
LY3074828  Term  Definition  
5-ASA  5-aminosalicylic acid  
6-MP 6-mercaptopurine  
AAULN  age-adjusted upper limit of normal  
ADA  anti-drug antibody  
ADR  adverse  drug reaction  
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An adverse event can therefor e be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
AESI  adverse events of special interest  
AIDS  acquired immunodeficiency syndrome  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
anti-HBc hepatitis B core antibody  
AST aspartate aminotransferase  
AZA azathioprine  
CD Crohn’s disease  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, qual ity, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CRF case report form  
CSR  clinical study report  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 114 
LY3074828  CT computed tomography  
CXR  chest x -ray 
DNA  deoxyribonucleic acid  
ECG  electrocardiogram  
eCOA  electronic clinical outcome assessment  
eCRF  electronic case report form  
EDC  electronic data capture  
EIM extraintestinal manifestation  
enroll  The act of assigning a  patient  to a treatment.  Patients  who are enrolled in the study are 
those who have been assigned to a treatment.  
enter  Patients  entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.  
ePPND  enhanced pre - and postnatal development  
ERB  ethical review board  
ES endoscopic subscore  
ETV early termination visit  
GDH  C. difficile antigen  
GMP  Good Manufacturing  Practice  
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
hs-CRP  high-sensitivity C -reactive protein  
IB Investigator’s Brochure  
IBD inflammatory bowel disease  
ICF informed consent form  
ICH International Council for Harmonisation  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 115 
LY3074828  IEC Independent Ethics Committee  
IGRA  interferon -γ release assay  
IL interleukin  
informed consent  A process by which a patient  voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient ’s decision to participate.  Informed consent is documented by 
means of a writt en, signed and dated informed consent form.  
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.  
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
markete d products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.  
IP investigational product  
IRB Institutional Review Board  
ITT intent -to-treat:  The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating on the basis of the intention to treat a patient  (that is, the planned 
treatment regimen) rather than the actual treatment given.  It has the consequence  that 
patients  allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.  
IV intravenous  
IWRS  interactive web -response system  
JAK Janus kinase  
LTBI  latent tuberculosis infection  
MedDRA  Medical Dictionary for Regulatory Activities  
MMS  Modified Mayo Score  
MTX  methotrexate  
NIMH  National Institute of Mental Health  
NOS  not otherwise speci fied  
NRI nonresponder imputation  
NRS  numeric rating scale  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 116 
LY3074828  PCR  Polymerase Chain Reaction  
PD pharmacodynamics  
PGA  Physician’s Global Assessment  
PGI-C Patient’s Global Impression  of Change  
PGRS  Patient’s Global Rating of Severity  
PK pharmacokinetics  
PPD purified protein derivative  
PRN  as needed  
PUCAI  Paediatric Ulcerative Colitis Activity Index  
Q4W  every 4 weeks  
Q12W  every 12 weeks  
RB rectal bleeding  
RNA  ribonucleic acid  
SAE serious adverse event  
SAP statistical analysis plan  
SC subcutaneous  
screen  The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.  
SF stool frequency  
SUSARs  suspected unexpected serious adverse reactions  
TASA  Treatment of Adolescent Suicide Attempters  
TB tuberculosis  
TBL total bilirubin level  
TEADA  treatment -emergent anti -drug antibody  
TEAE  treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.  
TNF tumor necrosis factor  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 117 
LY3074828  TST tuberculin skin test  
UC ulcerative colitis  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 118 
LY3074828  Appendix 2.  Clinical Laboratory Tests  
 
 
  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 119 
LY3074828   
Selected tests may be obtained in the event of systemic allergic/hypersensitivity events . 
Hypersensitivity Testsa 
Immunogenicity testing (ADA)  Tryptase   
Serum mirikizumab  concentration (PK)  Complement   
 Cytokine Panel 
Abbreviations:  ADA = anti-drug antibod y; PK = pharmacokinetic s. 
a Assayed by Lilly -designated laboratory and for immediate hypersensiti vity events  only. 
 
Laboratory  Test Prioritization  
Care should be taken to safeguard study participants with regard to the amount of blood drawn 
for study procedures .  All effort s have  been made to minimize required sampling in this protocol ; 
however, in the case of younger and lower body weight patients, the following guidance is 
provided .  Importantly , sites should follow local institutional review board  guidelines , where 
applicable.  Patients   old with body weight  lower than  will require reduced  blood 
volume collection , and some tests will need to be excluded.  In the situation where blood vo lume 
is limited and all tubes cannot be collected, the following sample tubes should be removed in this 
order:  
Please refer to the lab manual for collection tube volumes for each of the above mentioned tests.   
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 120 
LY3074828  Appendix 3.  Study Governance Considerations  
 
 
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 121 
LY3074828  Appendix  3.1. Regulatory and Ethical Considerations, Including the 
Informed Consent Process  
Appendix 3.1.1 . Informed Consent  
The investigator is responsible for:  
 Ensuring that the patient /patient’s legal representative  understands  the nature of 
the study , the potential risks and benefits of participating in the study , and that 
their participation is voluntary . 
 Ensuring that informed consent is given by each  patient  or legal representative.  
This includes obtaining the appropriate signatures and dates on the informed 
consent form ( ICF) prior to the performance of any protocol pro cedures and prior 
to the administration of investigational product.  
 Ensuring that informed consent is given by pediatric participants for continued 
participation once the patient  reaches the age of legal consent.  
 Answering any questions the patient/patient ’s legal representative may have 
throughout the study and sharing in a timely manner any new information that 
may be relevant to the patient ’s/patient’s legal representative ’s willingness to 
continue his or her participation in the study.  
 Ensuring that a c opy of the ICF is provided to the participant or the participant’s 
legal representative and is kept on file.  
 Ensuring that the medical record includes a statement that written informed 
consent was obtained before the participant was enrolled in the study a nd the date 
the written consent was obtained.  The authorized person obtaining the informed 
consent must also sign the ICF .   
A legal representative must give informed consent for a child to participate in this study.  In 
addition to the informed consent given by the legal representative, the child may be required to 
give documented assent, if capable.  
Appendix 3.1.2 . Recruitment  
Eli Lilly and Company ( Lilly ) or its designee is respo nsible for the central recruitment strategy 
for patients.  Individual inve stigators may have additional local requirements or processes.  
Appendix 3.1. 3. Ethical Review  
The investigator must give assurance that the ethical review board (ERB) was properly 
constituted and convened as required by International Council  for Harmonisat ion (ICH) 
guidelines and other applicable laws and regulations.  
Documentation of ERB approval of the protocol and the ICF and Assent Form must be provided 
to Lilly before the study may begin at the investigative site(s).  Lilly or its representatives must 
approve the ICF, including any changes made by the ERBs, before it is used at the investigative 
site(s).  All ICFs must be compliant with the ICH guideline on Good Clinical Practice ( GCP ). 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 122 
LY3074828  The study site’s ERB(s) should be provided with the following:  
 The protocol and related amendments and addenda , current Investigator ’s 
Brochure  and updates during the course of the study  
 Informed consent form  and Assent Form  
 Other relevant documents ( for example , curricula vitae  and advertisements)  
Appendix 3.1. 4. Regulatory Considerations  
This study will be conducted in accordance with  the protocol and with the: 
 Consensus ethics principles derived from international ethics guidelines, 
including the Declaration of Helsinki and Council  for International  Organizations  
of Medical  Sciences  International Ethical Guidelines  
 Applicable ICH GCP Guidelines  
 Applicable laws and regulations  
Some of the obligations of the sponsor will be assigned to a third  party.  
Appendix 3.1. 5. Investigator Information  
Physicians with a special ty in pediatric gastroenterology  and/or at least  of experience 
with pediatric  patients may participate as investigators in this clinical trial.  
Appendix 3.1. 6. Protocol Signatures  
The sponsor’s responsible medical officer will approve the protocol,  confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study.  
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signe d page to a Lilly representative.  
Appendix 3.1. 7. Final Report Signature  
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct a nd results 
of the study.  
An investigator will be chosen by Lilly to serve as the CSR coordinating investigator.  
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her  knowledge, the report accurately describes the 
conduct and results of the study.  
Appendi x 3.2.  Data Quality Assurance  
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following:  
 Provide instructional material to th e study sites, as appropriate  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 123 
LY3074828   Provide sponsor start -up training to instruct the investigators and study 
coordinators.  This training will give instruction on the protocol, the completion 
of the case report forms ( CRFs ), and study procedures.  
 Make periodic visits to the study site  
 Be available for consultation and stay in contact with the study site personnel by 
mail, telephone, and/or fax  
 Review and verify  data reported  to detect potential errors  
In addition, Lilly or its representatives will periodically check a sample of the  patient  data 
recorded against source documents at the study site.  The study may be audited by Lilly or its 
representatives, and/or regulatory agencies at any time.  Investigators will be given notice before 
an audit occurs.  
The inves tigator will keep records of all original source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct acce ss to original source 
documents.  
Appendix 3.2.1.  Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.  
An electronic data capture (EDC)  system  will be used in this study  for the collection of CRF 
data.  The investigator  maintains a separate source for the data entered by the investigator or 
designee  into the sponsor -provided EDC system .  The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by signing the CRF . 
Additionally, clinical outcome assessment data (questionnaires, scales, self -reported diary data, 
etc.) will be collected by the investigator site personnel, via a paper source document and will be 
transcribed by the investigator site personnel into the EDC system.  
Additionally, electronic clinical outcome assessment (eCOA) data (questionnaires, scales, self -
reported diary data, etc. ) will be directly recorded by the subject /caregiver/investigator  site 
personnel  into an instrument (for example, hand held smart phone or tablet, or by means of an 
interactive voice/web system) .  The eCOA data will serve as the source  documentation and the 
investig ator will not maintain a separate, written or electronic record of these data .   
Data collected via the sponsor -provided data capture syst em(s) will be stored at a third party.  
The i nvestigator will have continu ous access to the data during the study and until 
decommissioning of the data capture system(s).  Prior to de commissioning, the investigator will 
receive an archival copy of pertinent data for retention .   
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system  and electronic transfers will be provided to the investigator 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 124 
LY3074828  for review and retention .  Data will subsequently be transferred from the central vendor to the 
Lilly data warehouse.  
Data from compliant  forms submitted to Lilly will be encoded and stored in the global product 
compliant  management system.  
Appendix 3.3.  Study and Site Closure  
Appendix 3.3.1.  Discontinuation of Study Sites  
Study site participation may be discontinued  if Lilly or its designe e, the investigator, or the ERB 
of the study site  judges it necessary for medical, safety, regulatory, or other reasons consistent 
with applicable laws, regulations, and GCP.  
Appendix 3.3.2.  Discontinuation of the Study  
The study will be discontinue d if Lilly or its designee judges it necessary for medical, safety, 
regulatory, or other reasons consistent with applicable laws, regulations, and GCP.  
Appendix 3. 4. Publication Policy  
The publication policy for Study I6T-MC-AMB U (AMB U) is described in the lett ers of 
agreement between the sponsor and the investigators and institutions . 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 125 
LY3074828    
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 126 
LY3074828   
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 127 
LY3074828  Appendix 5.  Prohibited Medications  
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 128 
LY3074828  This section outlines medications that are prohibited during the treatment phase of the study and  
during washout periods prior to the screening endoscopy, if applicable.  Use of the medications 
listed in this appendix is allowed at the discretion of the investigator after a participant 
discontinues study drug and completes the ETV.  
Drug Class  Comment s 
Anti-TNF antibodies ( for example,  infliximab, adalimumab 
or golimumab)   Discontinue at least prior to screening 
endoscopy  and prohibited throughout duration 
of study  
Anti-integrin antibodies ( for example,  vedolizumab)  Discontinue at least prior to screening 
endoscopy  and prohibited throughout duration 
of study  
Agents depleting B or T cells ( for example,  rituximab, 
alemtuzumab, or visilizumab)  Discontinue at least prior to 
baseline; patients remain excluded if evidence 
of pe rsistent targeted lymphocyte  depletion at 
the time of screening endoscopy  
Immunomodulatory medications, including oral cyclosporine, 
IV cyclosporine, tacrolimus, mycophenolate mofetil, 
thalidomide , or Janus kinase (JAK) inhibitors ( for example,  
tofacitinib)  Discontinue at least  prior to screening 
endoscopy and prohibited throughout duration 
of study  
Intravenous corticosteroids  Discontinue at least prior to screening 
endoscopy and prohibited throughout duration 
of study  
Systemic corticosteroids for non -UC indications (oral or IV)  Patients requiring systemic corticosteroids for 
 for non -UC conditions are excluded.  
Exceptions include  
 
 
 
 
Topical corticoster oids and 5 -ASA therapies (enemas or 
suppositories)  Discontinue at least  prior to screening 
endoscopy and prohibited throughout duration 
of study  
Any investigational  therapy (biologic or non -biologic)  
 Discontinue at least , or 5 half -lives 
whichever is longer, prior to screening 
endoscopy and prohibited throughout duration 
of study  
Anti-IL12p40 antibodies ( for example,  ustekinumab 
[Stelara®]) or anti -IL-23p19 antibodies ( for example,  
risankizumab [BI -655066 /ABBV -066], brazikumab 
[MEDI -2070], guselk umab [CNTO1959], tildrakizumab 
[MK -3222]) for any indication, including investigational use  Patients with any previous exposure  of p19 
antibodies are  not eligible to be enrolled  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 129 
LY3074828  Drug Class  Comment s 
Medicinal and recreational marijuana (includes c annabidiol  
[CBD ] oil) Must be stopped prior  to enrollment .  
Marijuana use is prohibited for  the duration of 
the study.   If use is identified during the trial, it 
may result in discontinuation; consult the 
medical monitor.  
Abbreviations:  5 -ASA = 5 -aminosalicyclic  acid; IV = intravenous; TNF = tumor necrosis factor ; UC = ulcerative 
colitis . 
 
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 130 
LY3074828  Appendix 6.  Permitted Medications with Dose 
Stabilization  
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 131 
LY3074828  Drug Class  Comments  
Oral 5 -ASAs (for example, mesalamine, 
balsalazide, olsalazide)  May continue during study with stable doses encouraged  
Oral corticosteroids  Responder patients who are receiving oral corticoste roids at 
the start of Study AMB U will start corticosteroid taper at  
 
will begin corticosteroid tapering 
if symptomatic response or symptomatic improv ement based 
on investigator discretion is achieved at any time after 
starting extended induction (see Corticosteroid Taper  in 
Section  7.7.1 . 
Corticost eroids for non -UC indications:  
corticosteroids to treat adrenal insufficiency, as 
premedication for investigational product  
infusion, or locally administered corticosteroids 
(e.g., inhaled, intranasal, intra -articular, topical)  May continue corticosteroids to treat adrenal insufficiency or 
locally administered corticosteroids during study with stable 
dose encouraged.   corticosteroids 
as premedication to investigational product  administration are 
allowed  in patients with prior investigational product  or other 
previous biologic injection reactions.   A short course  
 is allowed to treat non -UC conditions . 
Immunomodulators (for example, AZA, 6 -MP, 
or MTX)  Prescribed dose will remain  unless 
medication is discontinued due to a toxicity related to the 
medication.   
 at the discretion of the investigator unless 
medication is discontinued due to a tox icity related to the 
medication  
Antidiarrheals (for example, loperamide, 
diphenoxylate with atropine)  May continue during study with stable doses encouraged  
Non-live (killed, inactivated or subunit) vaccines  Allowed during the study.  The efficacy of non -live 
vaccinat ions with concomitant m irikizumab treatment is 
unknown .  If a non -live vaccine is needed, it is recommended 
that study drug not be administered on the same day as a 
vaccination.   
Homeopathic and alternative treatments  Vitamins and probiotics are allowed.   Other non -prescription 
drug therapies may be permitted following discussion with 
the sponsor.  The dose of medication should remain constant 
for the 52 -week duration of the study  
Abbreviations:  5 -ASA = 5 -aminosalicylic acid;  6-MP = 6 -mercaptopurine; AZ A = azathioprine; IV  = intravenous ; 
MMX  = multi matrix colonic delivery technology; MTX = methotrexate ; UC = ulcerative colitis . 
 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 132 
LY3074828  Appendix 7.  Ulcerative Colitis Disease Activity  
Measures  
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 133 
LY3074828  Mayo Scoring System for the Assessment of Ulcerative Colitis Disease Activity  
  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 134 
LY3074828  PUCAI:  Pediatric Ulcerative Colitis Activity Index  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 135 
LY3074828  Appendix 8.  Risk Factors for Latent Tuberculosis 
Infection  
  
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 136 
LY3074828  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 137 
LY3074828  Appendix 9.  Examples of Infections that  May Be 
Considered Opportunistic in the Setting of Biologic 
Therap y 
  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 138 
LY3074828   
 
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 139 
LY3074828  Appendix 10.  Provisions for Changes in Study Conduct 
During Exceptional Circumstances  
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by the sponsor in partnership with the 
investigator.  
Exceptional circumstances  
Exceptional circumstances are rare events that may cause disruptions to the conduct of the study.  
Examples include pandemi cs or natural disasters.  These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by local regulations.  
After approval by local Ethical Review Boards, regulatory bodies , and any other relevant local 
authorities, impl ementation of these exceptional circumstance changes will not typically require 
additional notification to these groups, unless they have specific requirements  in which 
notification is required (for example, upon implementation and suspension  of changes ).  All 
approvals and notifications must be retained in the study records.  
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if needed.  
Considerations for making a change  
The prevailing consideration for making a change is ensuring the safety of study participants.  
Additional important considerations for making a change are compliance with Good Clinical 
Practice, enabling participants to continue safely in the study and ma intaining the integrity of the 
study.  
Informed consent  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 140 
LY3074828  Changes in study conduct during exceptional circums tances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.    
The following changes in study conduct will not be considered protocol deviations.  
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 141 
LY3074828  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 142 
LY3074828  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 143 
LY3074828  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 144 
LY3074828  Screening period guidance  
To ensure safety of study participants, laboratory values and other eligibility assessments taken 
at the scree ning visit are valid for a maximum of .  The following rules will be applied 
for active, nonrandomized participants whose participation in the study must be paused due to 
exceptional circumstances:  
 If screening is paused for less than  from s creening/lead -in visits to 
randomization visit:  the participant will proceed to the study visit per the usual 
Schedule of Activities, provided that  randomization visit  must be conducted within 
 from first screening procedure.  
o The site should conduct the randomization visit if the participant’s eligibility 
criteria are confirmed, and the site should document the reason for delay . 
o Due to the pause in screening, sites should also reconfirm the impacted 
participant’s legal guardian consent, partic ipants assent if not of legal age and 
document this confirmation in the source documentation.  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 145 
LY3074828   If screening is  paused for more than  from screening/lead -in visits to 
randomization visit and without an endoscopy procedure completed:  the participant 
must be discontinued because of screening interruption due to an exceptional 
circumstance.   This is documented as a screen fail ure in the CRF .  The participant can 
reconsent and be rescreened as a new participant.  [This rescreen is in addition to the 
one a llowed by the main protocol.]  The screening procedures per the usual Schedule 
of Activities should be followed, starting at  screening visit to ensure participant 
eligibility prior to randomization visit.  
Adjustments to Visit Windows  
Whenever possible and safe to do so, as determined by the investigator’s discretion, participants 
should complete the usual Schedule of Activities.  To maximize the possibility that these visits 
can be conducted as on -site visits, the windows for visits ma y be adjusted, upon further guidance 
from the sponsor.  This minimizes missing data and preserves the intended conduct of the study.  
This table describes the allowed adjustments to visit windows.  
Table 1:  Extended Visit Windows  
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 146 
LY3074828  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 147 
LY3074828  For participants whose visits have extended windows, additional study intervention may need to 
be provided to avoid interruption and maintain overall integrity of the study.  
Documentation  
Changes to study conduct will be documented  
 Sites will identify and document the details of how participants, visits types, and 
conducted activities were affected by exceptional circumstances.  
Dispensing/shipment records of study intervention and relevant communications, 
including delegation, shoul d be filed with site study records.  
Source documents at alternate locations  
 Source documents generated at a location other than the study site should be part of 
the investigator’s source documentation and should be transferred to the site in a 
secure and t imely manner.  
Approved on 23 Oct 2021 GMT
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 148 
LY3074828  Appendix 11.  Protocol Amendment I6T-MC-AMBU (b) 
Summary  
A Multicenter, Open -Label PK Study of Mirikizumab in 
Pediatric Patients with Moderately to Severely Active 
Ulcerative Colitis  
Overview  
Protocol  I6T-MC-AMBU(a) A Multicenter, Open -Label PK Study of M irikizumab in Pediatric 
Patients with Moderately to Severely Active Ulcerative Colitis  has been amended.  The new 
protocol is indicated by amendment ( b) and  will be used to conduct the study in place of any 
preceding version of the protocol.  
The overall ch anges and rationale for the changes made to this protocol are described in the 
following table:  
 
Approved on 23 Oct 2021 GMT
I6T-MC-AMBU (c) Clinical Protocol  Page 149 
LY3074828  Amendment Summary for Protocol I6T-MC-AMBU  Amendment ( b) 
Section # and Name  Description of Change  Brief Rationale  
Section 1. Synopsis  
Section 4 . Objectives and Endpoints  
Section 9.1 Efficacy Assessments, Table AMBU 5  Revised secondary objective wording for MMS 
clinical re mission definition  Endpoint has been updated based on revised 
regulatory expectations . 
Updated secondary objective mucosal he aling 
endpoint  Endpoint has been  updated for clarity from 
mucosal healing to histologic -endoscopic mucosal 
remission to align with other mirikizumab  
protocols . 
Section 2. Schedule of Activities  
TB monitoring  language was clarified  Clarification  of TB monitori ng process  to align 
with sponsor safety  guidance for TB assessments 
and other mirikizumab protocols . 
Addition of language for Stool culture and 
Clostridium difficile  toxin  In some cases, local la boratory testing results may 
be available sooner than the c entral lab results. 
Given the need to shorten the screening period for 
these sick chi ldren , the protocol will now allow  
specific C. difficile  local laboratory tests for 
screening into the study . 
Approved on 23 Oct 2021 GMT
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 150 
LY3074828  Section 2. Schedule of Activities  
Section 5.1. Overall Design  Additional footnote and language added for 
unscheduled visits   Footnote b was added  to the SoA to allow , with  
prior Sponsor approval,  additional dosing at 
Week  52 and beyond , after completing Visit 16 
procedures if participant is waiting for regulatory 
and/or ethics approval to enroll into Study AMAZ . 
This provision  was also added to the  overall study 
design  for clarity.  
Section 2. Schedule of Activities  
Section 9.1.6.3. Assessment of Puberty  
Section 9.4.3.2. Hormone Testing    
  
Section 5.1. Overall Design  Addition of wording to clarify inten ded use  of data 
snapshot  and how it pertains  to the opening of  
 group for enrollme nt Addition of wording to clari fy inten ded use  of data 
snapshot and  provide  align ment  with updates in 
Section 10.3.8.1. Data Snapshots  
Section 6.1. Inclusion Criteria  Addition of wording in inclusion criterion [2b] for 
female contraception  Clarification t hat 2 effective methods of 
contraception must continue  
 
 
Revision of language in hemoglobin inclusion 
criterion [11a]  Update of language to reference additional 
exclusion criterion [46] clarifying  a hematology 
blood sample cannot be drawn within  of a 
blood transfusion.  
Section 6.2. Exclusion Criteria  Revised language in exclusion criteria [19d], 
[19e], and [19i]  Clarification that therapies must be discontinued 
within designated time window prior to screening 
endoscopy.  
Removal of wording in exclusion criterion [23]  Removal of redundant wording on primary 
immune deficiencies as this is previously noted in 
exclu sion criterion [14].  
Additional language in exclusion criterion [26]  Further clarification for C difficile , other intestinal 
pathogens, and  
   
Revised language in exclusion  criterion [42]  Clarification of timing for enrollment for 
participants to require
 
after receiving last dose of study drug  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 151 
LY3074828  Clarification with a ddition of exclusion criterion 
[45]  Clarification to separate marijuana from illicit 
drugs  exclusion criteri on [43] to avoid potential 
confusion . 
Clarification with addition  of exclusion criterion 
[46] By requiring that hematology blood samples 
cannot be collected within  
 
 
 
 
Section 6.4. Screen Failures  Clarification  of inclusion/exclusion criteria 
numbers an d language related to rescreening  Clarification  of Inclusion/Exclusion  criteria 
numbers that weren’t  previously documented as 
allow ed or disallowed  for rescreening in the event 
of a screen failure.  
Section 6.4.1. Allowed Retesting of Screening 
Investigations  Removal of first paragraph and additional 
language added  Paragraph was removed to avoid redundancy and 
language was added for clarity.  
Section 7.1. Treatments Administered  Correction of typo for timing IV administration of 
mirikizumab and sentence removal  Correction of  typo for  IV administration time for 
mirikizumab to be  to align with 
investigational product administration instructions 
provided to the sites and removal of sente nce for 
clarity.  
Section 7.6. Treatment Compliance  
Section 9.1.1. Mayo Score  Clarification  language added and paragraphs 
moved from Section 7.6 to Section  9.1.1  Clarification of investigator responsibility for 
training of participant and paragraphs moved  to 
align with section in protocol discussing bowel 
preparation and UC symptom diary recording.  
Section 7.7.1. Corticosteroid Taper  Clarification language was added  Clarification that steroids can be tapered before 
following investigator judgement .  
Section 7.7.2. Vaccine Administration During the 
Study   
  
 
.  
Section 8.1.1. Permanent Discontinuation from 
Study Drug    
 
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 152 
LY3074828  Section 9.1.2. Endoscopy  Clarification of timing from baseline for those 
requiring full colonoscopy and additional wording 
for central readers  Timing for participants who require surveillance 
colonoscopy for UC associated dysplasia and 
malignancy noted  to be within  of 
baseline to align with surveillance guidance.  Also, 
clarification of procedures for central readers  
Section 9.1.9.3. Extraintestinal Manifestations  Clarification  of diagnoses  Updates for content regarding  extraintestinal 
manife station diagnoses.  
Section 9.4.5.1. Physical Examination  Clarification of language for TB screening 
physical examination  Clarification of physical examination for TB at 
screening for all participants.  
Section 9.4.5.2. Tuberculosis Testing  Clarification of language for monitoring for TB 
during the study  Clarification for interpretation of screening test for 
LBTI for patients with BCG vaccination history.  
Updated guidance for TB monitoring to be 
documented at least every  for each 
participant:  (1 ) to determine any risk factors for 
TB infection and progression; (2) and thorough 
physical examination for signs of active TB.  
Additions were made to align with updated Lilly 
safety guidance.  
Section 9.4.5.3. Chest Radiography  Clarification of language  for CXR  and allowance 
of a CT Scan in place of CXR  Clarified guidelines for CXR and additional 
language to allow  CT Scan based on regional 
standard of practice.  Additional guidance for the 
CXR or CT Scan for TB evaluation to be 
interpreted and reported b y a radiologist or 
physician specialized in the treatment of TB.  
Section 9.4.5.4. Hepatitis B Testing  Clarification of language for patient management  Clarification  for Management of Patients with a 
Newly Positive anti -HBc Test During the Study to 
give gu idance for management of this potential 
patient population during the study.  
Section 9.4.5.6. Depression and Suicidality  
Section 11 References  
Approved on 23 Oct 2021 GMT
CCI
CCI
CCI
CCI
I6T-MC-AMBU (c) Clinical Protocol  Page 153 
LY3074828  Section 9.4.5.7. Stool Testing  Additional language and flow chart for C. difficile  
testing  Clarification on C. difficile  screening using local 
and central testing.  A flow chart was added to 
clarify process for determining results for C. 
difficile  infection.   
Section 10.3.8.1. Data Snapshots  Update d language  Clarification of data snapshots for patients >40 kg.   
Section 10.3.8.2. Interim Analyses  Update d language  Clarification of interim analysis timing based on  
number of patients in the ≤40 kg group  necessary 
to make a dosing decision to enable Phase 3  trial. 
Appendix 2 Clinical Laboratory Tests  Addition of language for  hypersensitivity tests  Clarification of Lilly -designated laboratory to be 
used for immediate hypersensitivity events only.  
Appendix 5. Prohibited Medications  Revised language in comments section for 
anti-TNF antibodies, anti -  antibodies, and 
  Clarification that therapies must be discontinued 
within specified time window prior to screening 
endoscopy to align with exclusion criteria.  
Clarification of BCG and live attenuated vaccine 
and marijuana use including CBD oil  Clarification of  prohibited medications to align 
with other mirikizumab protocols.  
Appendix 6. Permitted Medications and Dose 
Stabilization  Clarification regarding  rectally administered 
medications  Clarification  of guidance for rectally administered 
5-ASA s and rectally administered corticosteroids 
to align with other mirikizumab protocols.  
Addition of language for non -live vaccines  Addition of recommendation noting study drug 
should not be administered on the same day as a 
vaccination.  
Appendix 10. Pr ovision for Changes in Study 
Conduct During Exceptional Circumstances  Addition of appendix  Provisions were added in the event of exceptional 
circumstances that may cause study disruptions 
and sites needing additional flexibility.  
Throughout  Minor typographical corrections , clarifications , or 
semantic changes  Changes do not affect content . 
 
Approved on 23 Oct 2021 GMT
CCI
CCI
Signature Page for VV-CLIN-008288 v1.0
Signature Page for VV-CLIN-008288 v1.0Approval
22-Oct-2021 20:48:56 GMT+0000
Approval
23-Oct-2021 00:58:37 GMT+0000
Approved on 23 Oct 2021 GMT
PPD
PPD